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Summary  
Activating BRAF mutations are frequently found in diverse types of cancer, 
including multiple myeloma. Moreover, current targeted therapy can abrogate 
mutant BRAF kinase activity although drug resistance mechanisms are still a 
challenge. However, this mutation has not been functionally characterized in 
multiple myeloma and biological consequences along BRAF inhibitor resistance 
mechanisms are unknown.  
Here we show that BRAF V600E expression in multiple myeloma leads to an 
active MAPK/ERK pathway and eventual DNA damage. This mutation can be 
targeted with BRAF inhibitors (BRAFi). Nevertheless, we demonstrate that BRAF 
wild type under BRAFi leads to paradoxical activation. To overcome this effect a 
MEK inhibitor was employed for an effective pathway abrogation in multiple 
myeloma. 
Furthermore, to identify mechanisms that contribute to BRAFi resistance, whole 
exome sequencing of a BRAFi-resistance model of MM was performed. We 
identified a novel mutation in the transcription factor EGR-1 followed by its 
protein functional characterization. This showed that the mutant protein (p. 
332fs) along the wild type protein is overexpressed in our in vitro model and 
mutant EGR-1 influences its own subcellular localization. Overexpression of the 
mutant EGR-1 conferred complete resistance to BRAF inhibition.  
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Zusammenfassung 
Aktivierende Mutationen in der BRAF Kinase werden in verschiedenen 
Krebsarten mit unterschiedlicher Häufigkeit nachgewiesen, unter anderem auch 
im Multiplen Myelom. Ferner sind die derzeitigen zielgerichteten Therapien in 
der Lage, die Kinaseaktivität des mutierten BRAFs zu unterbinden, wobei jedoch 
auftretende Medikamentenresistenzen eine Herausforderung darstellen. Diese 
Mutation wurde jedoch beim Multiplen Myelom noch nicht funktionell 
charakterisiert und die biologischen Folgen von Resistenzmechanismen gegen 
BRAF-Inhibitoren sind unbekannt.  
In dieser Arbeit zeigen wir, dass die Expression von BRAF V600E im Multiplen 
Myelom zu einer Aktivierung des MAPK/ERK Signalwegs führt und schließlich in 
DNA-Schäden resultiert. Diese Mutation kann mit BRAF Inhibitoren (BRAFi) 
gezielt spezifisch gehemmt werden. Dennoch zeigten wir wie es unter BRAFi-
Exposition des BRAF-Wildtyps zu einer paradoxen Aktivierung kommt. Um diese 
Wirkung zu umgehen wurde ein MEK-Inhibitor für eine effektive 
Signalwegblockade im Multiplen Myelom eingesetzt.  
Außerdem wurde eine vollständige Exomsequenzierung eines BRAFi-
Resistenzmodells durchgeführt, um Mechanismen zu identifizieren, die zur 
BRAFi-Resistenz beitragen. Wir identifizierten eine neue Mutation im 
Transkriptionsfaktor EGR-1, woraufhin eine funktionelle Charakterisierung 
dieses Proteins erfolgte. Diese zeigte, dass das mutierte Protein (p. 332fs) 
zusammen mit dem Wildtyp-Protein in unserem in vitro Modell überexprimiert 
wird und die EGR-1 Mutation die subzelluläre Lokalisation des Proteins 
beeinflusst. Zusätzlich führt die fehlerhafte Proteinexpression alleine zu einer 
Dabrafenib-Resistenz im Multiplen Myelom.  
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Introduction 
 
 
Multiple myeloma 
Multiple myeloma (MM) is a clonal disease of malignant plasma cells 
characterized by the excess of plasma cells in the bone marrow, along with high 
monoclonal protein levels in the blood or urine, osteolytic bone lesions, renal 
disease and immunodeficiency.  
On a worldwide scale, MM is estimated to represent approximately 1% of all 
new cancer cases and about 10% of hematologic malignancies. It is also 
considered to be the second most frequent blood neoplastic disease, accounting 
for 0.9% of all cancer-related deaths per year 1. The incidence of MM is higher in 
the industrialized regions of Europe, North America, Australia and New Zealand 
than in the rest of the world. Ethnically, it occurs almost double as frequent in 
blacks compared to whites, and in terms of age at diagnoses, the median ranges 
from 63 to 71 years. In regard to gender, this disease is more predominant in 
males than in females. Currently, the median overall survival is about 5 years 2.  
MM is regularly preceded by a premalignant state, termed monoclonal 
gammopathy of undetermined significance (MGUS). The pathogenesis of MM is 
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thought to embrace a multistep process from early genetic events such as 
hyperdiploidy and immunoglobulin translocations, followed by secondary 
genetic events such as copy number abnormalities (gain and losses of entire 
DNA regions), acquired mutations and DNA hypomethylation that lead to tumor 
cell diversity and disease progression (Figure 1) 3–5. 
The most predominant chromosomal aberrations include translocations of the 
Heavy Chain Locus (IGH@) on chromosome 14 as a result of switch 
recombination or somatic hypermutation causing spiked expression of 
oncogenes positioned near Ig enhancers 6. Some reported translocations that 
lead to an upregulated gene expression are, t(4;14) FGFR3 and MMSET, t(6;14): 
CCND3,  t(11:14): CCND1, t(14;16): MAF, t(14;20): MAFB3,4.  
The secondary genetic events comprehend mutations, overexpression or 
activation of functional sequelae such as G1/S transition, proliferation, 
resistance to apoptosis, NF-κB pathway, bone disease, abnormal plasma 
differentiation, abnormal DNA repair, RNA editing, epigenetic abnormalities 7. 
Moreover, genetic abnormalities affect the expression of adhesion molecules in 
myeloma cells, responsible for the interaction with bone marrow stromal cells 
and the extracellular matrix proteins. This can influence cell migration, survival, 
growth and drug resistance. As it has been described for other types of cancer, 
interaction with the microenvironment results in the upregulation of cell cycle 
and antiapoptotic proteins, leading to disease progression 8. 
The current treatment is based on proteasome inhibitors like bortezomib and 
carfilzomib, immunomodulatory drugs including thalidomide, lenalidomide and 
pomalidomide, and conventional chemotherapy drugs such as melphalan. 
However, relapse occurs inevitably and it becomes harder over time to provide 
an effective therapy since tumor cells acquire resistance 9. Thus, new therapeutic 
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approaches are urgently needed to overcome treatment resistance in multiple 
myeloma. 
 
 
 
 
 
 
 
 
 
The MAPK/ERK pathway 
The mitogen-activated protein kinase (MAPK) pathway is involved in the 
regulation of cell differentiation, proliferation, and survival. The activation of 
this pathway is triggered by diverse cytokines, such as interleukin-6 (IL-6) and 
interleukin-21(IL-21), vascular endothelial growth factor (VEGF), tumor 
necrosis factor-α (TNFα), stromal cell derived factor-1 (SDF-1) or the insulin-
like growth factor-1 (IGF-1)10–12 .  
These mitogens activate the membrane receptors of the respective receptor 
tyrosine kinases (RTK) family such as fibroblast growth factor receptor (FGFR), 
epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
Figure 1. Pathogenesis of multiple myeloma. Early aberrations occur in the germinal 
center of B cells, which lead to MGUS with hiperdiploidy and IGH@ translocations. These 
last contribute to increased genomic instability and to secondary genetic events found in 
MM. Additional genetic lessions cause the terminal phase called plasma cell leukemia.  
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receptors (PDGF-R). Once bound to the ligand the receptor auto-phosphorylates 
tyrosine residues and recruits docking proteins like SHC, GRB2, and SOS 
allowing the activation of the guanosine triphosphate (GTP) dependent RAS 
protein. In consequence, membrane-associated RAS-GTP recruits and activates 
the RAF family kinases (A, B and C-RAF), leading to the dimerization of RAF 
molecules. These dimers phosphorylate and activate the MAPK/ERK kinase 
(MEK 1/2) that in turn phosphorylates ERK 1/2 on residues T202/185 and 
Y204/187 (Figure 2). Active ERK1/2, targets hundreds of downstream 
substrates that regulate the expression of genes involved in proliferation, cell 
cycle progression, differentiation and  in the MAPK negative feedback, (Figure 2)  
13,14. There are more than 650 direct targets of ERK identified, including 
transcription factors (c-Jun, c-Fos, STAT1/3, c-Myc, N-Myc, UBF, ATF2 , Elk1),  
kinases and phosphatases (BRAF, CRAF, MEK1/2, RSK1-4, MKP3, MSK1/2) 
cytoskeletal proteins (Paxillin, Annexin XI, Laminin B2), signaling proteins 
(EGFR, IRS1, LAT, PLCβ, TSC2), apoptotic proteins and proteinases (Bad, Bim-EL, 
Caspase 9, MCL-1) among other targets15–18.  
Regarding the MAPK negative feedback loop of the MAPK/ERK pathway, it 
comprises diverse regulators of the same pathway  such as dual-specificity 
phosphatases  (DUSP) and  Sprouty proteins (Spry)19–21. 
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The MAPK/ERK pathway in multiple 
myeloma  
Recently, tumor genome sequencing data has shed light on the mutational status 
of different genes that contribute to the pathogenesis of multiple myeloma. The 
Ras pathway has the most noticeable rate of recurrent mutations being 
detectable in about 50% of the patients, highlighting the importance of the study 
of these genes along with the respective signaling pathways to discern a better 
understanding of this disease.  
Remarkably, in 4% of newly diagnosed and 8% refractory multiple myeloma 
patients the gene encoding for the serine-threonine kinase, BRAF was mutated 
mainly at the V600E position, conferring activation of this protein 22–25. 
Figure 2 Overview of the MAPK/ERK pathway. The phosphorylation events on the 
kinases, precedes the phosphatases activity which regulate the pathway. Activated ERK is 
translocated to the nucleus where it phosphorylates transcription factors such as Elk-1.  
Crosstalk activation of the PI3K/AKT pathway is also shown31.. Copyright 2017 by Nature 
Publishing Group.  Reprinted with permission  
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Importantly, MM patients refractory to all approved therapeutic options with 
multiple extramedullary lesions have successfully been treated with the 
mutation-specific BRAF inhibitor vemurafenib. Low doses of this compound 
were able to induce a stable remission of more than 8 months. This is the first 
evidence of the clinical and therapeutic relevance of the BRAF V600E mutation 
in multiple myeloma, proving the principle of specific inhibition of driver 
mutations in this disease 23,26. Nevertheless, resistance to vemurafenib is still a 
challenge in MM, recent results of the follow-up of the one patient showed 
acquired spatially heterogeneous NRAS mutations G13R, G12A, and Q61H, yet 
clonal within the lesions27.  
Recent studies in other types of cancer that contain the BRAF V600E mutation, 
like malignant melanoma and hairy cell leukemia, had demonstrated the benefit 
of targeting this mutation with specific drugs such as vemurafenib 28–30. 
However, single agent treatment with BRAF inhibitors, as shown in several 
malignancies, carries the risk of tumors developing early drug resistance31,32 
 
Serine/threonine-protein kinase BRAF  
Originally, the characterization of the RAF oncogenes was derived from the 
discovery of the murine sarcoma virus 3611 (MSV) and the avian retrovirus Mill 
Hill 2(MH2) and were found to transform epithelial cells and fibroblasts, 
inducing rapidly accelerated fibrosarcomas (RAF) in mice 33. The human 
homolog C-RAF was discovered in 1985, shortly followed by A-Raf (1986) and 
BRAF (1988). Since then many studies have contributed to the current 
knowledge about these kinases in normal and pathological conditions.   
The v-Raf murine sarcoma viral oncogene homolog B (BRAF) is a human gene 
located on chromosome 7 at position 7q34 containing 21 exons that encode an 
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mRNA of 2480 base pairs.  The BRAF protein has 766 amino acids and a 
molecular weight of approximately 86 kDa.  
 
BRAF structure 
BRAF contains three conserved domains, Ras-GTP binding domain, a serine-rich 
hinge region and a catalytic domain The protein has two lobes; the N-lobe 
residues 457-530 binds adenosine triphosphate (ATP) while C-lobe residues 
535-717 bind to substrate proteins. The active site is located within the cleft 
between both lobes (Figure3) 34,35 . The kinase domain contains a DFG motif 
formed by D594, F595, and G596, and it is involved in the inactive and active 
state  of the enzyme by regulating its interaction with ATP’s phosphate groups36. 
Furthermore, to be fully activated, BRAF has to dimerize via hydrogen bonding 
and electrostatic interactions of its kinase domains to another monomer of C-
RAF or BRAF 10 . 
 
 
 
 
 
 
 
Figure 3 BRAF protein scheme.  BRAF has three conserved domains, CR1 with a Ras-GTP 
binding domain, CR2 with a serine-rich hinge region and CR3 with the catalytic domain. For 
membrane docking the enzyme has a phorbol-ester/DAG type motif. The P-loop stabilizes the 
non-transferable phosphate groups of ATP, while ATP is anchored to the Nucleotide Binding 
Pocket and the DGF motif allows transferring the phosphate group to enzyme’s 
substrates37,131,132.  
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Mutant BRAF in cancer  
In 2002, Davies and colleagues described, for the first time, mutations in the 
BRAF gene in a wide range of human cancers 37. Almost 90% of BRAF mutations 
account for the substitution of valine (V) for glutamic acid (E) at position V600. 
This point mutation occurs within the activation segment of the protein, which 
leads to a constitutively active state of BRAF in a monomeric form. Another 
recurrent hotspot is the substitution of lysine (K) for asparagine (N) at the 
position K601 (0,2% in melanoma )38. Upon mutation, the mutant kinase 
becomes independent of upstream signals leading to a strong activation of the 
MAPK pathway, enhancing its oncogenic effect 39.   
Inactivating BRAF mutations have also been reported but are quite sporadic, 
some of them are the kinase-inactive variants BRAF D594A/V and K483M. 
Importantly, the combination of an activating Ras mutation with an inactive 
BRAF kinase can lead to tumor progression upon BRAF inhibition in mice 40. 
 
RAS/MAPK pathway inhibitors 
BRAF inhibitors 
BRAF inhibitors (BRAFi) are divided into two types, based on selectivity towards 
the kinase. Type 1 inhibitors are designed to selectively target mutant activated 
BRAF (active conformation “DGF-in”) two examples used in this work are 
described below.  
Vemurafenib (PLX4032, marketed as Zelboraf,) is a selective BRAF V600E that 
binds to the DFG-in (Asp-Phe-Gly) motif of the activation loop in the active 
kinase, blocking MEK/ERK phosphorylation 14,28,31.  
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This BRAFi can induce upon inhibition of ERK phosphorylation cascade, the 
expression of Bim, which triggers caspase 9 leading to subsequent caspase 3 
activation enhancing apoptosis. Vemurafenib also up-regulates endoplasmic 
reticulum (ER) stress-related genes as, p8, CHOP, TRB3, ATF4, and ATF3 by 
blocking sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) and increasing the 
concentration of cytosolic calcium. As result of higher expression of pro-
apoptotic proteins and ER-stress related genes, the BRAF mutated cells go into 
apoptosis 41.  
During phase III trials of vemurafenib, it was demonstrated its clinical efficacy in 
malignant melanoma patients with a BRAF V600E mutation at six months under 
treatment with a confirmed overall response rate of 84% in the vemurafenib 
group and 64% in the dacarbazine group (control arm) and a median 
progression-free survival of approximately 5 months for vemurafenib and 2 
months for dacarbazine 28,30.  
Dabrafenib (GSK2118436, trade name Tafinlar,) is a reversible ATP-competitive 
RAF inhibitor, which has a wider target spectrum than vemurafenib, targeting 
BRAF V600E (IC50 0.8nM), BRAF wild type (IC50 3.2nM and C-RAF (5nM)42. 
Preclinical data proved that dabrafenib inhibits the MAPK pathway in BRAF 
V600E in vitro and in vivo models by decreasing proliferation and inducing 
tumor regression in xenografts mice models 42,43. Clinical studies in melanoma 
showed its benefits, with a median progression-free survival of 5 months for 
dabrafenib and 2.7 months for dacarbazine (control arm) and a response rate of 
50% for dabrafenib and 6% for control arm 44,45 .  
In contrast, type 2 inhibitors bind to kinase’s inactive conformation known as  
“DFG-out” where F595 blocks ATP binding of the enzyme’s nucleotide-binding 
pocket 36. Nevertheless, these drugs  failed to show clinical efficacy for BRAF 
inhibition, an example is Sorafenib, a first generation of BRAF inhibitor, that 
targets C-RAF, BRAF wild type, BRAF mutant, vascular endothelial growth factor 
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receptor 2 (VEGFR2), vascular endothelial growth factor receptor 3 (VEGFR3), 
platelet-derived growth factor (PDGF) , p38 MAPK, FLT, cKIT, FMA, and RET 46.  
Along with the discovery of specific BRAF inhibitors, downstream MAPK 
inhibitors have been developed to specifically block MEK1/2 and ERK1/2 
activity.  
 
MEK inhibitors 
Trametinib is a competitive allosteric MEK inhibitor (MEKi) which was the first 
of its kind to be approved for clinical use. Trametinib clinical data in metastatic 
melanoma patients carrying a BRAF V600E/K mutation disclosed median 
progression-free survival of approximately 5 months and 1.5 months in the 
chemotherapy group (control arm). At 6 months, the overall survival was >80% 
in the trametinib group and <70% in the chemotherapy group 47,48. Moreover 
combined therapy with dabrafenib and trametinib showed a better outcome in 
melanoma patients (BRAF V600E/K) with a response rate of 76% in comparison 
to 59% single dabrafenib treatment and 40% single trametinib treatment and 
median progression-free survival was of 9.4 months for combined therapy while 
for dabrafenib alone was 6.9 months and trametinib alone was 5.7 months 48,49.  
 
ERK inhibitors 
ERK upstream therapy focuses in abrogating ERK phosphorylation, therefore a 
next logical step in inhibitor development is to target directly ERK with small 
molecule inhibitors such as SCH772984, GDC-0994, Ulixertinib, etc. 
Nevertheless, information on safety, drug combinations, and resistance 
mechanisms are still under investigation 50,51.  
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Paradoxical RAF activation 
The characterization of the crystal structure of BRAF was a breakthrough step in 
understanding physiological dimerization of the protein and how certain 
mutations such as V600E or K601N can change the enzymatic conformation to 
an activated state. Moreover, it led to the discovery of specific BRAF inhibitors.   
BRAF inhibitors can induce transactivation of wild type BRAF because they 
change the enzyme conformation to an “open state” leading to its dimerization. 
For example, vemurafenib binds only to one monomer provoking an allosteric 
transactivation of the drug-free monomer and downstream sequelae of the 
RAS/MAPK pathway are activated.  Transactivation of BRAF caused by BRAFi 
can be even further enhanced in tumors already carrying a RAS activating 
mutation, since active RAS-GTP also promotes BRAF dimerization. Strategies to 
prevent/overcome this paradoxical activation include an increased BRAFi dose 
that blocks both RAF monomers and their kinase activity (Figure 4), however 
toxicity is still a clinical dare, and also continuous dosis can lead to faster drug 
resistance. For this reason different therapeutic strategies have been developed 
such as drug holiday or re-challenge of BRAF/MEK inhibitor 52–55.  
Recent findings showed that BRAF inhibition can lead to the development or 
promotion of second primary neoplasias, such as cutaneous squamous cell 
carcinoma (cuSCC) and keratoacanthomas (KA). This secondary effect is mainly 
due to insufficient dose of the drugs leading to transactivation of BRAF wild type 
giving a paradoxical activation of the MAPK/ERK pathway mainly observed in 
presence of pre-existing RAS mutations which also promotes RAF dimerization 
and activates the same pathway. The incidence of cuSCC for vemurafenib-treated 
patients is 20-26% and dabrafenib-treated is 6-11%. Combined BRAFi and MEKi 
therapy  diminishes cuSCC to 7% of patients receiving both drugs but it was not 
exempt 56.   For this reason, a new class of RAF inhibitors was recently 
developed. One of this is the paradox breaker 04 (PB04/PLX7904) which blocks 
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ERK1/2 activation in mutant BRAF cells and did not enhance ERK1activation in 
NRAS and HRAS cell lines, or even in BRAF/NRAS co-expressing melanoma cells  
this occurs because this molecule was design to bind to the enzyme similarly as 
vemurafenib does but the difference is that PB04 along aminoacid Leu505 on the 
enzyme interact to each other and leads to a slight change of conformation, 
disrupting a RAF dimer formation which does not occur in the case of other 
BRAFi’s57,58.  
 
 
 
 
 
BRAF inhibitors mechanism of resistance 
The striking initial responses to BRAF inhibitors fascinated the scientific and 
clinical community because it meant a great achievement in cancer targeted 
Figure 4 Paradoxical RAF activation.  At baseline, BRAF wild type without stimulation 
remains inactive. While upon addition of non-saturating concentrations of the inhibitor 
BRAF is transactivated leading to an overactive MAPK/ERK pathway. In contrast, high 
inhibitor concentrations efficiently abrogate downstream signaling. 
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therapy. Nonetheless, the main obstacle of this targeted therapy drug resistance, 
mainly due to reactivation of the ERK signaling which promotes tumor re-
growth in almost all patients with a median progression-free survival of 5-7 
months.  
 
Tumor microenvironment 
A recent study demonstrated that innate BRAF inhibitor resistance is mainly due 
to the secretion of hepatocyte growth factor (HFG) by stroma cells of the tumor 
microenvironment. The secretion of this cytokine results in the MET activation, 
which in turn triggers a sustained signaling of both MAPK and PI3K/Akt 
pathways facilitating cell proliferation in BRAF inhibitor resistant cell lines. 
Additionally combination treatment in-vitro with BRAF inhibition and MEK 
inhibition was not sufficient to overcome HGF-induced resistance  59.   
 
NF1 loss 
NF1 is mainly a RAS GTPase activating protein (RAS GAP) that inhibits RAS 
activity. 
Moreover preclinical models on vemurafenib resistance showed RAS activation 
after the loss of the tumor suppressor NF1 reducing the sensitivity to BRAFi in 
BRAF V600E cells 60,61. About 4% BRAF mutant melanoma patients contain 
inactivating NF1 mutations. Active RAS is sufficient to induce BRAFi resistance 
in BRAF V600E cells 62.   
 
BRAF copy number gain 
A screening study compared baseline versus disease progression in melanoma 
patients after BRAF inhibitor treatment and found that 20% of the relapse 
samples had a BRAF gene amplification with copy-number gains from 2-13 fold. 
Moreover, higher doses of specific inhibitor or treatment with a MEK inhibitor in 
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preclinical cell models overexpressing BRAF V600E, have shown to overcome a 
hyperactivated MAPK/ERK pathway 63,64.  
 
BRAF splicing variant 
The expression of the p61 BRAF V600E isoform had been reported in a 
vemurafenib-resistant cell line SKMEL-238. This protein variant lacks exons 4-8 
corresponding to the encoding region of RBD in BRAF. This isoform leads to the 
high dimerization of the protein, thereby activating MEK. Although the enzyme 
retains sensitivity towards BRAFi, the high RAS-independent dimerization 
strongly triggers the MAPK/ERK pathway.  In addition, other in-frame splice 
variants derived from patients with acquired vemurafenib resistance had been 
documented such as p41, p48 and p55 which all contain an active kinase domain 
65.   
 
Activation of tyrosine kinase receptors 
Upregulation and activation of tyrosine kinase receptors (RTK) as Axl, ERBB2, 
PDFGRB, IGF1-R1 have been described as a secondary event under BRAFi 
treatment favoring cancer cell survival. Additionally, the activation of these 
receptors may be due to an increased intrinsic tumor cell ligand secretion or 
paracrine ligand production by stromal cells66.  
 
NRAS mutations 
Several studies in different types of cancer like leukemia, colorectal cancer, 
thyroid cancer and melanoma demonstrated that secondary activating RAS 
mutations can promote RAF dimerization and confer resistance to BRAF 
inhibitors by sustained activation of the MAPK/ERK pathway promoting tumor 
growth independently of upstream activation. Moreover, the PI3K pathway is a 
main effector of RAS contributing to cell growth, cell cycle progression and cell 
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survival. NRAS mutations like G12D, G13R and Q61K have been detected in 18% 
of progressive melanoma tumors while KRAS mutations such as G12C, G12R and 
Q61H were found in 7% of progressive melanoma tumors 57,67–69.   A recent 
study in a multiple myeloma patient carrying a BRAF V600E mutation treated 
with low dose vemurafenib developed a disease relapse due to clonal 
heterogeneity of tumor cells since 3 different lesions harbored 3 independent 
clonal NRAS mutations (G12A, G13R and Q61H), to overcome/prevent further 
development of resistance the patient was treated with a combination of BRAF 
and proteasome inhibitors23,70. 
 
C-RAF over-expression 
Studies in vitro had demonstrated that melanocytes under BRAF inhibitor 
switched BRAF dependency to C-RAF over-expression which increases 
phosphorylated ERK 1/2 levels resulting in an active MAPK/ERK pathway 71,72. 
 
COT over-expression 
In a selective RAF kinase inhibitor study, the gene MAP3K8 (encoding COT) was 
identified as an in vitro resistance mechanism due to its ability to constitutively 
activate ERK through a MEK-dependent mechanism that bypasses RAF signaling 
even in presence of the inhibitor. Furthermore, COT expression has been 
observed in tissues from relapsing patients after BRAFi or MEKi treatment 73.  
 
MEK mutations 
Secondary activating MEK1/2 mutations can confer BRAFi resistance because 
they can trigger the MAPK/ERK pathway independently of upstream signals. 
Some of the reported mutations include Q56P, K57E, V60E, C121S, G128V, 
E203K for MEK 1 and  V35M, L46F, F57C,  C125S,  N126D for MEK214,74–76.    
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PTEN Loss  
In vivo studies demonstrated that concurrent expression of BRAF V600E and 
silencing of the tumor suppressor PTEN gene led to development and metastasis 
of tumors in all mice  77. In the clinic, >10% of melanoma patients (BRAF 
V600E/K) present a loss of this phosphatase. An in-vitro study demonstrated 
that the absence of this enzyme facilitates AKT expression triggering cell 
survival even in the presence of BRAFi78. 
 
Cyclin D1 overexpression 
Cell cycle deregulation is a common feature in cancer, it occurs when there is an 
abnormal expression of cyclins and cyclin-dependent kinases (CDKs) which in 
consequence lead to uncontrolled proliferation, genomic instability (GIN) and 
chromosomal instability (CIN) favoring further disease progression 79,80 .  
Cyclin D1 regulates cyclin dependent kinases (CDKs) 4 and 6 which form a 
complex which phosphorylates the retinoblastoma protein (Rb) promoting cell 
cycle progression. A mutational screening in BRAF inhibitor resistant melanoma 
cells identified that resistance was mainly due to a CDK4 mutation (R24C, R24L, 
and K22Q) and CCND1 amplification. Of clinical relevance, CCND1 is amplified in 
almost  20% of BRAF V600E melanoma patients and  multiple myeloma patients 
independently of BRAF status81,82.  In the case of MM, CCND1 gene amplification 
is also associated to higher expression of MDR1 in comparison to CCND1 
negative patients. To our knowledge aberrant expression of cyclin D1 and 
mutant BRAF along with BRAF inhibitor resistance in MM has not been 
described.   
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Overcome BRAF inhibitor resistance 
Several studies, using different BRAFi as monotherapy, have reported a short 
duration of response. Therefore, it is important to develop more effective 
strategies such as combination and sequential therapies with other inhibitors.  
A common strategy is targeting the same MAPK/ERK pathway with a 
combination of a BRAF inhibitor and a MEK inhibitor, for example in a phase II 
study in metastatic melanoma the combination of dabrafenib and trametinib 
improved the median progression-free survival (PFS) of 9.4 months compared 
with 4-6 months for single-agent treatment 49. Nevertheless, in approximately 
50% of the patients treated with dabrafenib and trametinib resistance 
mechanisms could be identified at disease relapse , conferred by BRAF 
amplification (36%), activating NRAS mutations (18%) and MEK2 mutation 
C125S (9%)  83.  
Furthermore, targeting multiple signaling pathways simultaneously could avoid 
possible cancer cell dependence on other cell survival signaling. In vitro studies 
demonstrated that combination of dabrafenib, trametinib and GSK2126458, a 
phosphoinositide 3-kinase/mTOR inhibitor, improved cell growth inhibition in 
BRAF mutant cell lines 84. Phase I studies testing multi-targeted combinations 
with the PI3K inhibitor and trametinib showed that patient safety is still a 
clinical challenge 85.  Currently, there are also other open phase I/II  trials 
exploring combination therapies with the Akt inhibitor GSK2141795 and 
trametinib 86. 
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Research Objectives 
 
 
Recent clinical studies have reported activating BRAF mutations in 4- 10% MM 
patients, which can be successfully treated with targeted therapy. However, drug 
resistance occurs rapidly, limiting the duration of response. Moreover, the 
activating role of BRAF mutations in MM pathophysiology is poorly defined. 
Therefore, a better understanding of the biological impact of these aberrations 
and the resistance mechanisms against BRAF inhibitors in MM is of utmost 
importance to rationalize targeted therapy.  
The aim of this study was to decipher the cellular consequences of activating 
BRAF mutations in MM and, especially, to elucidate cell specific resistance 
mechanisms to BRAF inhibitors.  
For this purpose, two in vitro cellular models were developed and characterized, 
one focusing on conditional overexpression of BRAF wild type or V600E and 
another model to examine resistance mechanisms to pharmaceutical BRAF 
inhibition.  
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Materials and Methods 
 
Materials 
Biological materials 
Eukaryotic cell lines 
Table 1. Cancer cell lines 
 
Cell Line Description Source / Reference 
OPM-2 
Multiple myeloma cell line with 
wild type Ras pathway 
Katagiri et al. 1985 
U266 
Multiple myeloma cell line with 
mutation BRAF K601N 
Nilsson et al. 1970 
HeLa adenocarcinoma Gey 1952 
A375 malignant melanoma Giard et al. 1973 
Lenti-X™ 293T kidney Clontech, Takara Bio Company 
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Bacterial material 
Table 2. Bacterial material 
 
 
Genetic material 
DNA primers 
Primers for sequencing and polymerase chain reaction (PCR) were obtained 
from Eurofins MWG Operon (Ebersberg, Germany). 
Table 3. Primers  
Name Usage Sequence 
5prBRAFNheI 
For production of 
vector pLV.MIR-
Neo TRE BRAF 
GGAGCTAGCATGGCGGCGCTGAGC 
3prNheIBRAFmut 
For production of 
vector pLV.MIR-
Neo TRE cBRAF 
V600E 
GGAGCTAGC  TCAGTGGACAGGAAACGC 
3prBRAFXbaI 
For production of 
vector pLV.MIR-
Neo TRE cBRAF WT 
GGATCTAGATCAGTGGACAGGAAACGC 
Q5SDM_2/11/2016_F Mutagenesis CCCCCCCCACGAACGCCCTT 
Name Genotype Source / Reference 
E.coli DH5 alpha 
F- φ80lacZΔM15 Δ(lacZYA argF) 
U169recA1endA1 hsdR17 
(rKmK+) phoA supE44 thi- 
1gyrA96 relA1 λ- 
Stratagene, La Jolla, 
California, USA 
E. coli SCS110 
rpsL thr leu endA thi-1 lacY galK galT 
ara tonA tsx dam dcm supE44 ∆(lac-
proAB) 
Agilent Technologies, Inc., Cedar 
Creek, Texas, USA 
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Q5SDM_2/11/2016_R CGTCTTGCTGGGCCGGTTG 
3prBRAF FLAG-C 
PCR 
GTTGTAAAACGACGGCCAGT 
5pr_rtTAM2 ATG TCT AGA CTG GAC AAG AGC AAA GTC 
3pr_rtTAM2 TTA CCC GGG GAG CAT GTC AAG GTC AAA 
5pr_BRAFV600E in 
FLAG-C 
AGAACCCTCCTTGAATCGGG 
3pr_BRAFV600E in 
FLAG-C 
AGAGAGCTATGACGTCGCAT 
ACTB_FWD 
Semiquantitative 
PCR 
CATGTACGTTGCTATCCAGGC 
ACTB_REV CTCCTTAATGTCACGCACGAT 
FWD_N-EGR1 TGACCGCAGAGTCTTTTCCT 
REV_N-EGR1 TGGGTTGGTCATGCTCACTA 
FWD_C-EGR1 AAAGTGTTGTGGCCTCTTCG 
REV_C-EGR1 GGGGAACAGAGGAGTACGTG 
EGR-1_FWD 
Sequencing 
GCCCTCAATACCAGCTACCA 
EGR-1_REV AAGTTGCGCATGCAGATG 
STK36_FWD GGGCTATGAGCACCAATACAATG 
STK36_REV AAAGCAGGGACTGATGGTTG 
CACNA2D3_FWD_2 ACGGTTATGCCTTTGCAATC 
CACNA2D3_REV_2 CGTTTCCCTTTGTCCACTGT 
5’ EGR1_dupC 994 CCAGCAAGACGCCCCCCCCACGAAC 
3’ EGR1_dupC 994 GTTCGTGGGGGGGGCGTCTTGCTGG 
 
Expression constructs  
Table 4. Expression plasmids 
Name Backbone Vector type 
Antibiotic 
resistance 
Insert Source 
pLV.MIR-Neo 
pLV Tet-
IRES-
mCherry 
Mammalian 
Expression, 
Lentiviral 
Ampicillin 
/Neomycin 
- 
Dr. Daniel 
Novak, Clinical 
Cooperation 
Unit Dermato-
Oncology, 
FUdeltaGW-
rtTA 
FUdeltaGW 
Ampicillin 
/Zeocine 
reverse 
tetracycline 
 Functional characterization of BRAF mutations in multiple myeloma  
34 
 
transactivator 
(rtTA) 
German Cancer 
Research 
Center, 
Heidelberg, 
Germany 
pCMV- EGR1 
cDNA clone 
pCMV-ORF 
Mammalian 
Expression 
Ampicillin 
/Hygromycin 
EGR1 cDNA 
clone 
Sino Biologicals 
Inc. Catalog No. 
HG11870-G-N 
 
 
Table 5. Expression constructs used for mammalian cell transduction or 
transfections  
Backbone 
Vector 
Name 
Vector type 
Antibiotic 
resistance 
Insert Source 
pLV.MIR-
Neo TRE 
BRAF WT 
pLV Tet-
TRE 
BRAF 
WT-
IRES-
mCherry 
Mammalian 
Expression, 
Lentiviral 
Ampicillin 
/Neomycin 
BRAF 
wild type 
Produced during this 
work 
pLV.MIR-
Neo TRE 
BRAF MUT 
pLV Tet-
TRE 
BRAF 
V600E-
IRES-
mCherry 
BRAF 
V600E 
pCMV- 
EGR1 MUT 
pCMV-
ORF 
Mammalian 
Expression 
Ampicillin 
/Hygromycin 
EGR1 
dupC944 
pLenti 
EGR-1  
pLenti 
EGR-1 
IRES GFP 
Mammalian 
Expression 
Ampicillin/ 
Blasticidin 
EGR1 wt 
or mut 
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Antibodies 
Primary Antibodies for Western Blot 
Table 6.  Primary antibodies used for western blot 
Antigen Clone Species Clonality Dilution Source 
MCM7 141.2 mouse monoclonal 1:1000 Santa Cruz 
Alpha tubulin DM1A mouse monoclonal 1:1000 Abcam 
Erk1/2 (p44/42 
MAPK) 
- rabbit 
ployclonal 
 
1:1000 
Cell Signaling 
Technologies 
phospho-ERK 1/2 
(Thr202/204) 
- rabbit 
ployclonal 
 
1:1000 
Cell Signaling 
Technologies 
Phospho-BRAF 
(Ser445) 
- rabbit polyclonal 1:1000 
Cell Signaling 
Technologies 
BRAF  (N-
terminus) 
H-145 rabbit polyclonal 1:1000 Santa Cruz 
BRAF  (C-
terminus) 
C-19 rabbit polyclonal 1:1000 Santa Cruz 
BRAF V600E VE-1 mouse monoclonal undiluted 
Dr. med. David 
Capper, Pathology 
Institut, 
Neuropathology, 
Heidelberg 
University 
phospho-MEK1/2 
(S217/221) 
- rabbit polyclonal 1:1000 
Cell Signaling 
Technologies 
MEK1/2 - Rabbit polyclonal 1:1000 
Cell Signaling 
Technologies 
EGR-1 44D5 rabbit monoclonal 1:1000 
Cell Signaling 
Technology 
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Secondary Antibodies for Western Blot 
Table 7. Secondary antibodies used for western blot 
Antigen Specifications Species (clonality) Dilution Source 
Mouse IgG HRP-conjugated Goat (p) 1:5000 Santa Cruz 
Rabbit IgG HRP-conjugated Goat (p) 1:5000 Santa Cruz 
 
Enzymes 
Table 8.  Enzymes  
Name Source 
T4 DNA ligase 
New England Biolabs, Ipswich, UK 
Restriction endonucleases 
DNAse I Sigma-Aldrich Munich, Germany 
Phusion® High-Fidelity DNA Polymerase 
Thermo Fisher Scientific, Lafayette, CO, USA 
Shrimp Alkaline Phosphatase 
RNAse A 
VWR International GmbH, Darmstadt, 
Germany 
 
Molecular weight markers 
Table 9. Molecular weight markers used for agarose electrophoresis or 
western blot 
Name Source 
LowRanger DNA Ladder 
Thermo Fisher Scientific (Fermentas Life Science), 
Waltham, MA, USA 
HighRanger DNA Ladder Norgen Biotek, Ontario, Canada 
Precision Plus Protein ™Dual Color 
Standards 
Bio-Rad Laboratories, Hercules, CA, USA 
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Kits 
Table 10. Kits used in this work 
Name Source 
Quick Start TM Bradford Protein Assay 
Bio-Rad Laboratories, Hercules, USA 
iScript™ cDNA Synthesis Kit 
Q5® Site-Directed Mutagenesis Kit New England Biolabs, Ipswich, UK 
Cell Titer-Glo® Luminescent Viability Assay Promega, Madison, USA 
Midi/Maxi Plasmid Purification Kit 
Qiagen, Hilden, Germany 
QIAamp DNA Mini Kit 
QIAprep® Spin Miniprep Kit 
QIAQuick® Gel Extraction Kit 
RNeasy Mini Kit 
High Pure PCR Product Purification Kit Roche, Basel, Switzerland 
Pierce® ECL Western Blotting Substrate Thermo Scientific, Waltham, USA 
Vectashield® 
Vector Laboratories, Burlingame, USA 
Vectashield® with DAPI 
Lenti-X™ GoStix™ 
Clontech Laboratories, Inc. A Takara Bio, Shiga 
Japan 
Senescence β−galactosidase staining kit 
Cell Signaling Technology, Danvers, 
MA, USA 
 
Chemicals 
List of sources for molecular biological grade or purest reagents (chemicals, 
antibodies, enzymes, etc.) employed during this work.  
Abcam Cambridge, UK; AppliChem Darmstadt, Germany; BD Biosciences 
Heidelberg, Germany; Biochrom Berlin, Germany;  Bio-Rad Munich, Germany;  
Biozym Scientific GmbH Oldendorf, Germany;  Carl Roth Karlsruhe, Germany;  
Cell Signaling Technology Danvers, USA; Dyomics Jena, Germany, Eppendorf 
Hamburg, Germany; Exbio Prague, Czech Republic; GE Healthcare 
Buckinghamshire, UK; Gibco Eggenstein, Germany;  Ibidi Munich, Germany; Life 
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Technologies Darmstadt, Germany; Merck Millipore Bedford, USA; New 
England Biolabs Frankfurt, Germany; Proteintech Manchester, UK; QiagenHagen, 
Germany; Roche Basel, Switzerland; Roche Diagnostics Mannheim, Germany; 
Santa Cruz Heidelberg, Germany; Selleck Chemicals München, Germany; Serva 
Heidelberg, Germany; Sigma-Aldrich Munich, Germany;  Thermo Fisher Scientific 
Lafayette, CO, USA and Vector Laboratories Burlingame, USA.  
 
Consumables  
GE Healthcare Chalfont St Giles, UK; Greiner Bio-One Kremsmuenster, Austria; 
Starlab Hamburg, Germany; Sarstedt Nuembrecht, Germany; Eppendorf  
Hamburg, Germany. 
 
 
Media, buffers and solutions 
Media for bacterial culture 
LB medium:  1% w/v Trypton,  0.5% w/v Yeast extract,  pH 7.2 
LB-agar:  LB medium,  1% w/v NaCl,  1.5% w/v Agar, stored 4°C 
SOC medium: 2% w/v Trypton,  0.5% w/v Yeast extract, 0.05% w/v NaCl,  2.5 
mM KCl10,  mM MgCl2,  20 mM Glucose,  pH 7.0 
 
Media and solutions for cell culture 
Table 11. Media and solutions for cell culture 
 Name Source 
TC10 Trypan Blue Dye 0,4% Bio-Rad Laboratories GmbH, Munich, Germany 
Trypsin/EDTA-solution 
0,25% (v/v) Pig-trypsin (Gibco®/Invitrogen, 
Carlsbad, USA) in PBS/EDTA 
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PBS/EDTA 2 mM EDTA in PBS 
Fetal Calf Serum (FCS) Biochrom, Merck Millipore, Berlin Germany 
L-Arginine 
Fisher Scientific 
L-Lysine Dihydrochloride 
L- Arginine:HCl (13C6; Arg+6) / Arg+6 
L-Lysine: 2HCl (4,4,5,5-D4; Lys+4) / Lys+4 
L-Arginine:HCl (U-13C6, 15N4; Arg+10)/ 
Arg+10 
RPMI 1640 
Gibco®/Invitrogen, Carlsbad, USA DMEM 
OptiMEM 
Fetal Bovine Serum dialyzed (dFCS) 
Sigma-Aldrich St. Louis, USA 
Poly-L-Lysine 
SILAC RPMI 
Thermo Scientific (Life Technologies) 
PrestoBlue® Cell Viability Reagent 
 
 
Buffers and reagents 
Table 12.  Buffers and reagents 
Name Description/Source 
10X Methanol transfer buffer 
Tris 50mM 
Glycine 40mM 
SDS 3,7g 
ddH2O 1000mL 
1X Methanol transfer buffer 
10X Methanol transfer buffer 100mL 
Methanol 200mL 
ddH2O 700mL 
10X Running Buffer for SDS-
PAGE 
Glycin  30,3g 
Tris 144,1g 
SDS 10g 
1X Phosphate-buffered saline 137 mM NaCl 
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(PBS) 2,7 mM KCl 
10 mM Na2HPO4 
1,7 mM KH2PO4 
pH 7,4 
1X RIPA buffer 
50 mM Tris/HCl pH 7.5 
150 mM NaCl 
0.25% w/v Sodium-deoxycholate 
1% v/v Nonidet P40 
1 mM EDTA 
1 Tablets/10 ml Complete protease inhibitor, Roche, Basel, 
Switzerland 
1X TBS 
10mM Tris-HCl 
150mM NaCl 
pH 8.0 
1X TBTS 
1X TBS 
0.1% (v/v) Tween-20 
6X SDS loading buffer 
Tris/HCl pH 6.8 240 mM 
Β-mercaptoethanol 30% v/v 
SDS 6% w/v 
Glycerol 30% v/v 
Bromophenol blue 0.002% w/v 
6X DNA loading dye 
100 mM Tris/HCl pH 7.5 
200 mM EDTA 
0.01% w/v Bromophenol blue 
0.01% w/v Xylencyanol 
30% v/v Glycerol 
Borate transfer buffer 
Boric acid 20 mM 
EDTA 1.3 mM 
pH 8.8 
NP40-Lysis-buffer 
50 mM Tris-HCl pH 7,5-7,8 
150 mM NaCl 
0,5% NP40 
5 mM NaF 
1 mM Na3VO4 
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1 Tablets/10 ml Complete protease inhibitor, Roche, Basel, 
Switzerland 
Trihydrocloride, trihydrate 
Hoechst 33342 
Life Technologies Darmstadt, Germany 
Acrylamide/ Bis 37.5:1 
solution (30% w/v) 
Serva Electrophoresis, Germany 
Ammonium Persulfate (APS) Carl Roth GmbH, Germany 
Blocking buffer 
immunofluorescence 
10% Goat serum  in 1X PBS 
Blocking buffer Western Blot 5% Bovine serum albumin in PBST 
 
 
Antibiotics 
Table 13.  Antibiotics used during this work 
Name Source 
Carbemicillin 
Serva, Heidelberg, Germany Final concentration: 
100µg/mL 
Geneticin (G418) PAA Laboratories GmbH (Austria) 
Zeocine 
Sigma-Aldrich St. Louis, USA Tetracycline 
hydrochloride 
Doxycycline 
hydrochloride 
VWR International GmbH, Darmstadt, Germany 
 
Drugs 
Table 14.  Chemicals used for cell culture experiments 
Chemical Source 
Vemurafenib (PLX4032) 
Selleck Chemicals, München, Gemany Dabrafenib (GSK2118436) 
Trametinib (GSK1120212) 
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Etoposide Promokine, Heidelberg, Germany 
5-Fluoroacil 
Sigma-Aldrich St. Louis, USA Cytochalasin B 
Cisplatin 
Doxorubicin hydrochloride 
Biomol GmbH, Hamburg, Germany Vincristine sulfate 
Paclitaxel 
 
Table 15. Doxycycline concentration used for transgene induction  
Cell line Doxycycline concentration 
OPM-2 BRAF WT 1 μg/mL 
OPM-2 BRAF V600E 1 μg/mL 
 
Laboratory equipment 
Table 16.  Equipment used during this work. 
Name Source 
BD Accuri C6 Flow cytometer Becton Dickinson, San Jose, USA 
Mini-PROTEAN® Tetra Cell 
Bio-Rad Laboratories Hercules, CA, 
USA 
Mini Trans-Blot® Electrophoretic Transfer 
Cell Bio-Rad Laboratories 
TC20™ automated cell counter 
Fluorescence microscope Axiovert 200M 
equipped with AxioCam MRm 
Carl Zeiss, Jena, Germany 
Fluorescence microscope Axioskop 
equipped with AxioCam MRc 
PCR-Machine „Mastercycler gradient“ 
Eppendorf Hamburg, Germany PCR-Machine „Mastercycler personal“ 
Photometer 
Centrifuge 5417R Eppendorf Hamburg, Germany 
Centrifuge Megafuge 1.0R Heraeus, Hanau, Germany 
UV Table Konra Benda, Wiesloch,Germany 
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Confocal Microscope Leica TCS SP5 Leica Wetzlar, Germany 
pH-Meter SevenMulti Mettler Toledo, Giessen, Germany 
Spectrophotometer “NanoDrop” 
PeqLab Biotechnologie Erlangen, 
Germany 
Shandon Cytospin III 
Thermo electron 
corporation,Pittsburg, USA 
Centrifuge Sorvall RC6Plus Thermo Scientific, Waltham, USA 
 
 
Software 
AxioVision Version 4.7.2 Carl Zeiss, Göttingen, Germany; BD Accuri C6 Becton 
Dickinson, San Jose, USA; ImageJ Wayne Rasband, USA;  Microsoft Office 2010 
Microsoft Corporation, Redmond, USA;  NEBaseChanger™ New England Biolabs, 
Ipswich, UK;  SerialCloner 2.6.1 SerialBasics, http://serialbasics.free.fr;  ZEN lite 
2011 Carl Zeiss, Göttingen, Germany; Chipster Helsinki, Finland;  Ingenuity® 
Pathway Analysis IPA®, QIAGEN Redwood City, USA, 
www.qiagen.com/ingenuity;  DAVID Bioinformatics  Resources 6.7 National 
Institute of Allergy and Infectious Diseases (NIAID), NIH, Maryland, USA.; 
Panther University of Southern California, Los Angeles, USA;  InkscapeSoftware 
Freedom Conservancy, Inc., New York, USA; GraphPad Prism version 7 for 
Windows, GraphPad Software, La Jolla California USA, www.graphpad.com.  
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Methods 
Molecular biology methods  
 
Isolation of plasmid DNA  
To analyze recombinant DNA, the isolation of plasmids was performed from the 
host cell.  Briefly, transformed bacteria colonies were isolated and transferred to 
liquid cultures at 37°C in LB medium. For small scale preparation (mini-prep) 
5mL of liquid culture was incubated for 8 hours while for larger scale 
preparation (maxi-prep) 1 mL of mini-prep culture was then transferred to 100 
mL liquid culture and incubated overnight.  
 
Cultivation of bacteria  
E. Coli DHα were cultured in lysogeny broth (LB) or plated on LB-agar and 
grown at 37°C under continuous shaking. Bacteria were selected under 
appropriate antibiotics. Depending on the preparation scale, purified DNA was 
obtained either using QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany) or 
QIAGEN Plasmid Maxi Kit (Qiagen, Hilden, Germany) and followed according to 
manufacturer’s instruction. DNA concentration was determined by measuring 
the 260/280 nm absorbance ratio using a NanoDrop 2000 spectrophotometer 
(PeqLab Biotechnologie, Erlangen, Germany).  
 
Cloning 
BRAF genes were isolated from plasmids pCMV BRAF C-FLAG and pCMV BRAF 
V600E C-FLAG, generously provided by Dr. David Capper from Pathology 
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Institute, Neuropathology from Heidelberg University. Once the sequence was 
verified, the BRAF genes were amplified by polymerase chain reaction (PCR) 
with primers containing NheI and XbaI restriction sites. Afterward, the correct 
size fragments (2,3kb) were visualized in a 1% agarose gel. The PCR products 
were purified by column using the High Pure PCR Product Purification Kit 
(Roche, Basel, Switzerland).  
 
Digestion  
Digestion of the vector was done with NheI and XbaI restriction endonucleases 
enzymes (New England Biolabs, Ipswich, UK) as indicated by the manufacturer. 
Then, the digested vector was dephosphorylated with 10UI Shrimp Alkaline 
Phosphatase (Thermo Fisher Scientific, Waltham, MA, USA) at 25°C for 2 hours. 
The digested vector was purified by agarose gel electrophoresis and gel 
extraction using the QIAQuick Gel Extraction Kit, according to manufacturer’s 
instructions.   
 
Ligation 
The insert and the vector were ligated with T4 DNA ligase (New England Biolabs, 
Ipswich, UK) by setting up the reaction as follows, 2µL 1010X T4 DNA Ligase 
Buffer, 100ng vector DNA, 75ng insert DNA, 1µL T4 DNA Ligase and up to 20µL 
Nuclease-free water. As negative control same reaction was perform except with 
insert. The ligation was incubated at 16°C overnight. Next day, the enzyme was 
inactivated at 65°C for 10 minutes.  A 1-5µL product of ligation was used for 
bacterial transformation.  All reactions were assembled on ice.  
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Bacterial transformation 
10-100ng of DNA from ligations or vectors was used for bacterial 
transformation. Briefly,  50µL of competent bacteria were thawed on ice. The 
DNA was added to the thawed bacteria and samples were incubated on ice for 1 
hour. Subsequently, heat shock was employed by exposure to the bacteria to 
42°C for 45 seconds and immediate ice incubation for 2 minutes. Then, 250-
500µL of SOC medium was added, and samples were incubated at 37°C shaking 
horizontally at 1400rpm for 1 hour. Bacteria were centrifuged at 3000rpm for 4 
minutes and resuspended in 100µL of SOC medium, plated in LB plates with 
antibiotics. LB plates were incubated at 37°C overnight.  
 
Site-directed mutagenesis 
Mutagenesis of pCMV- EGR1 cDNA clone was done using the Q5® Site-Directed 
Mutagenesis Kit (New England Biolabs, Ipswich, UK) as indicated by the 
manufacturer. To design the primers to insert a base pair, the software 
NEBaseChanger™ was employed.  
Table 17. Example of PCR protocol 
Component 25 µL reaction Final conc. 
Q5 Hot Start High-Fidelity 2X Master Mix 12.5 µL 1X 
10 μM Forward Primer 1.25 µL 0.5 μM 
10 μM Reverse Primer 1.25 µL 0.5 μM 
Template DNA (1–25 ng/µL) 1 µL 1-25 ng 
Nuclease-free water 9.0 µL 
 
Step Temp Time 
Initial Denaturation 98°C 30 seconds 
25 Cycles 
98°C 10 seconds 
50–72°C* 10–30 seconds 
72°C 20–30 seconds/kb 
 Functional characterization of BRAF mutations in multiple myeloma  
47 
 
 
 
Agarose gel electrophoresis  
For DNA size fragment separation, agarose gel electrophoresis was performed. 
1% - 2% agarose gels were prepared with 0.1 µL/mL ethidium bromide in TAE 
buffer. DNA samples were prepared with 6X loading dye and were run at 100V 
for 1 hour in an electrophoresis chamber (Bio-Rad Laboratories, Hercules, USA). 
DNA fragments were visualized by UV light in a gel documentation system. 
 
RNA extraction and cDNA synthesis 
Total RNA extraction was done using RNeasy Mini Kit (Qiagen, Hilden, 
Germany), following manufacturers specifications. RNA concentration and 
purity was measured at 260nm/280nm in a NanoDrop 2000 
Spectrophotometer. RNA was subjected to DNAse I treatment (Sigma-Aldrich 
Munich, Germany), agreeing manufacturer’s specifications. For the 
complementary DNA synthesis (cDNA), the iScript™ cDNA Synthesis Kit Bio-Rad 
(Munich, Germany) was employed according manufacturer’s instructions.  
 
Polymerase chain reaction (PCR)  
To amplify interest regions of genomic DNA or cDNA, a polymerase chain 
reaction (PCR) was performed using Phusion® High-Fidelity DNA Polymerase 
(Thermo Fisher Scientific, Lafayette, CO, USA), following manufacturer’s 
instructions.  
 
Final Extension 72°C 2 minutes 
Hold 4–10°C 
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Gene expression profiling  
Gene expression profiling (GEP) of induced cell lines expressing BRAF WT or 
V600E and U266 Dabrafenib resistant cell lines was performed. The inducible 
OPM-2 cell lines BRAF wild type or V600E were under doxycycline (1µg/mL) for 
24h. U266-R cells were washed and subsequently total RNA (RNeasy Mini Kit, 
Qiagen, Hilden, Germany),) from both cell lines was extracted. RNA 
concentration of 50ng/µL and 500 ng in total was sent to the microarray unit of 
the DKFZ Genomics and Proteomics Core Facility for providing the Gene 
Expression Profiling which was carried on the Illumina HT12v4 platform. The 
data was processed in chipster 91. The selection of genes from microarray was 
within a defined fold range of greater than 1.5-fold and less than 0.75-fold. 
Statistical significance was analyzed by two group empirical Bayes test. The 
value of P<0.05 was considered significant.  
 
Sanger sequencing  
30-80ng/µL purified PCR or plasmids dissolved in 20µL nuclease-free water 
were sent for Sanger sequencing (GATC Biotech, Konstanz, Germany). Analysis 
of the sequence was performed in Chromas Lite 2.01 (Technelysium Pty Ltd, 
South Brisbane Australia) software. 
 
Next generation sequencing 
50ng/µL of total DNA from cell lines with a was extracted with the QIAamp DNA 
Mini Kit (Qiagen, Hilden, Germany) with a final volume of 20µL and then for the 
next generation sequencing (NGS) the Ion AmpliSeq™ Cancer Hotspot Panel v2 
with Ion Torrent Next Generation Sequencing was employed by A. Böhnisch or 
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A. Brütgens from the Molecular Diagnostics department at the Institute of 
Pathology Heidelberg (IPH).  
 
Whole exome sequencing 
Total DNA was extracted with the QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany), and a concentration of 50ng/µL and 3µg in total was sent to High 
Throughput Sequencing Unit of the DKFZ Genomics and Proteomics Core 
Facility. For library preparation “Exome-seq SureSelectXT Human v5+UTRs” was 
used and for sequencing an Illumina sequencing system “HiSeq 2000” with a 
paired-end read of 100bp length was employed. Whole exome sequencing (WES) 
data was kindly processed by Sadaf Mughal and Dr. Benedikt Brors from the 
Division Applied Bioinformatics, DKFZ and NCT Heidelberg, Heidelberg, 
Germany.  
 
Methods in cytogenetics 
Interphase FISH 
1-5x104 cells per sample were diluted in 200µL 1XPBS, and transferred to the 
sample chambers and immobilized on glass slides by cytospin centrifugation 
(Thermo Fisher Scientific, Lafayette, CO, USA) at 400rpm for 5 minutes. Then 
cells were air dried and fixed with ice-cold methanol: glacial acetic acid for 10 
minutes. Interphase FISH with probes for 5q31/5q33/6cen and 
13q14/18q21/21q22 and quantification of at least 200 cells was performed by 
Michaela Brough or  Dr. Anna Jauch from the Institute of Human Genetics, 
University Hospital Heidelberg.  
 
 Functional characterization of BRAF mutations in multiple myeloma  
50 
 
Metaphase spread of human myeloma cell lines 
70% confluent cells were used in a final volume of 20ml media. Then cell were 
treated with 10µg/ml colcemid for 2h at 37°C followed by centrifugation at 
1200rpm for 10min. Hypotonic treatment of the samples  with KCl 0,55%, 
0.075M was slowly added and incubated for 10min. Cells were fixed with 2ml of 
methanol / glacial acetic acid, 3:1 and centrifuged for 10min at 1200rpm. Cell 
pellets were resuspended in 5ml supernatant. Second step of 20ml fixative was 
followed and centrifuged three times at same speed and time as previously 
mentioned. For dropping, the cells were added to clean slides from 50cm height 
and spread over waterbath at 56°C. Control of mitotic index (1-2 mitoses/field) 
was perfomed at bright field microscope (20X objective).  Samples were stored 
at -20°C. 
 
Multicolor FISH and karyotyping 
Multiplex fluorescence in situ hybridization of myeloma cell lines (U266 parental 
and U266R) were prepared. Fifteen metaphase spreads were analyzed and 
presented as multicolor karyograms. These experiments were perfomed by 
Brigitte Scholer in the laboratory of Prof. Dr. Anna Jauch, Department of Human 
Genetics at Heidelberg University. 
 
Methods in protein biochemistry 
Protein lysates for western blot analysis  
Suspension cells were harvested by centrifugation and then washed once with 
1XPBS. Cell pellets were resuspended in RIPA buffer supplemented with 
Complete Protease Inhibitor (Roche, Basel, Switzerland) and PhosSTOP 
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Phosphatase Inhibitor Cocktail (Roche, Basel, Switzerland). The samples were 
incubated on ice for 30 minutes and then centrifuged at 10,000rpm for 10 
minutes. The supernatant was transferred into new tubes and stored at -80°.  
 
Bradford protein assay  
The colorimetric protein Bradford assay was employed to determine protein 
concentration. 1mL dye reagent for the Quick Start Bradford Protein Assay (Bio-
Rad, Munich, Germany) and 1µL of the protein lysate was mixed and incubated 
for 5 minutes. Then absorbance at 595nm was measured by spectrophotometry 
(Eppendorf, Hamburg, Germany) using a BSA standard curve as reference 
 
Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE gels self-made were used to separate proteins according to their 
molecular weight. Usually 10-12% acrylamide running gels (1,5 M Tris pH 8.8 
0.4 % SDS) with stacking gels (1,0 M Tris pH 6.8 0.4 % SDS). 30µg of protein in 
1X SDS loading buffer were incubated at 95°C for 5 minutes and then loaded to 
the gel. Separation of proteins was at 120V in Mini-Protean Tetra cells (Bio-Rad, 
Munich, Germany) filled with 1X Running buffer for SDS-PAGE. 
 
Western blot 
Separated proteins from the SDS-PAGE were transferred onto a nitrocellulose 
blotting membrane (GE Healthcare Life Sciences, Chalfont St Giles, UK). An 
assembled sandwich ((cathode) fiber pad, filter paper, membrane, gel, filter 
paper and fiber pad (anode)) was collocated in the electrode module of the Mini 
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Trans-Blot Electrophoretic Transfer cell (Bio-Rad, Munich, Germany) along ice 
cold transfer buffer and transfer was performed at 400 mA for 70 minutes. 
After transfer, the membranes were blocked for with 5% skimmed milk powder 
in 0.1% Tween-20 with TBS (TBS-T) for 1 hour. Primary antibodies were diluted 
in blocking solution and incubated with membranes overnight.  Then the 
membranes were rinsed three times with TBS-T for 5 minutes.  They were 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibody 
solution at room temperature for 1 hour. Three more washes with TBS-T were 
followed.  
The signal from HRP-conjugated secondary antibodies was identified by 
enhanced chemiluminescence method with Pierce ECL western blotting 
substrate (Thermo Fisher Scientific, Lafayette; USA) according to manufacturer’s 
instructions. Photographic films (Amersham Hyperfilm ECL GE Healthcare 
Buckinghamshire, UK) were exposed to HRP signal and developed. Alternatively, 
the membranes were developed in a ChemiDoc touch Imaging System (Bio-Rad 
Laboratories, Inc., Hercules/California, USA) following manufacturer’s 
instructions. Image analysis was performed in the Image Lab (Bio-Rad 
Laboratories, Inc., Hercules/California, USA) software. 
 
Methods  in cell biology  
Cell cultures  
A complete list of the cell lines employed in this work is provided in Table 18  
All cell lines were maintained at 37°C with 5% CO2 atmosphere. Cells were 
cultured in cell culture flasks or dishes with appropriate growth medium as 
described in Table 18. 
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Table 18.  Cell culture media and supplements Medium RPMI and DMEM  
Medium Supplements 
Selection 
antibiotics 
Cell line 
RPMI-1640 
(2 mM L-glutamine, 
10 mM HEPES, 1 mM 
sodium pyruvate, 
4500 mg/L glucose, 
and 1500 mg/L 
sodium bicarbonate) 
10% FCS, None OPM-2, U266, 
RPMI-1640 
 
10% FCS, 1,25µM Dabrafenib 
U266 dabrafenib 
resistant cell lines 
(U266-R): clones 3C, 
3F, 5E, 7E and 9D 
RPMI-1640 
 
10% tetracycline-
free FCS 
300µg/mL Zeocin 
400µg/mL G418 
OPM-2 conditional 
BRAF WT: clones 9 
and 16  or BRAF 
V600E: Clones 2, 4G, 
12 and 19 
DMEM 
(4 mM L-glutamine, 
4500 mg/L glucose, 1 
mM sodium pyruvate, 
and 1500 mg/L 
sodium bicarbonate) 
10% FCS None HeLa, A375 
DMEM 
 
10% FCS 
100 IU/mL Penicillin 
100 µg/mL 
Streptomycin 
None Lenti-X™ 293T 
Light SILAC RPMI 
1640 
10% dFCS 
100 IU/mL Penicillin 
and 100 µg/mL 
Streptomycin 
0.131 mM L-Arginine 
None OPM-2, U266 
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0.315 mM L-Lysine 
Dihydrochloride 
Medium SILAC RPMI 
1640 
10% dFCS 
100 IU/mL Penicillin 
and 100 µg/mL 
Streptomycin 
0.132 mM L- 
Arginine:HCl (13C6; 
Arg+6) / Arg+6 
0.32 mM L-Lysine: 
2HCl (4,4,5,5-D4; 
Lys+4) / Lys+4 
None 
OPM-2 BRAF WT 
clones 
Heavy SILAC RPMI 
1640 
10% dFCS 
100 IU/mL Penicillin 
and 100 µg/mL 
Streptomycin 
0.133 mM L-
Arginine:HCl (U-
13C6, 15N4; 
Arg+10)/ Arg+10 
0.313mM L-Lysine: 
2HCl (13C6, 15N2) / 
Lys+8 
None 
OPM-2 BRAF V600E 
clones and U266-R 
clones 
Growth media were stored at 4°C.  
 
Subcultures of suspension cell lines, the cultures were maintained by addition or 
replacement of fresh medium.  Cell density was preserved between 3*10^5 and 
1x10^6 cells/mL. 
 
Subculture of adherent cells, growth medium was removed and cells were rinsed 
with PBS-EDTA. 
Trypsin-EDTA solution was added and incubated at 37°C until cells were 
detached from the vessel.  Fresh medium was transferred to inhibit trypsin 
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activity. The subsequent cultivation ratio was 1:3 or 1:8 and they were seeded in 
a new vessel.  
 
Cryopreservation of cell lines 
To store cells, cell cultures were harvested and centrifuged for 5 minutes at 800 
x g. Growth medium was removed and cells were suspended in an ice-cold 
freezing medium (90% FCS and 10% DMSO) at 1*106 cells/mL 1 mL aliquots 
were transferred to cryovials. Cryovials were transferred to -80°C overnight and 
then moved to liquid nitrogen. 
 
Poly-l-lysine coating 
Sterile coverslips were placed in a 10cm dish, followed by 100µL of Poly-l-lysine 
(Sigma-Aldrich, Munich, Germany) for 20 minutes at room temperature.  Then 
three washes with sterile ddH2O were performed and the coated coverslips 
were stored at 4°C until use. 
 
Cell growth curves 
Cell growth was evaluated by Trypan blue exclusion cell count and PrestoBlue® 
Cell Viability Reagent proliferation assay. Cells were plated in a 24-well plate for 
Trypan blue exclusion cell count and 96-well plates for the PrestoBlue® 
proliferation assay. Cells were counted at 24-h intervals. PrestoBlue® was 
detected by luminescence (excitation 560nm and emission 590nm) in a 
microplate reader Infinite® 200 PRO series (Tecan Trading AG, Männedorf, 
Switzerland). Samples were in triplicates.  
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Drug-response curves 
For drug response curves 0.5*10^4 or 1*10^4cells per well with 50µL media 
were seeded in a 96 well plate. Then the drug was serially diluted and 50µL (2X 
of final concentration) were added to cells and incubated at 37°C, 5% CO2. After 
24, 48, 72, 96 or 120 hours a luminescent viability assay with Cell Titer Glo 
(Promega Mannheim, Germany) was performed in a microplate reader Infinite® 
200 PRO series (Tecan Trading AG, Männedorf, Switzerland). Statistical analysis 
of the data was performed using Excel software (Microsoft Corporation, 
Redmond, USA).  
 
In vitro development of dabrafenib drug-resistant cell line 
 0.3x10^6 cells/mL in 5mL of RPMI 1640 medium were seeded in 25 cm2 flasks. 
As the control, a flask named “parental” was untreated and maintained along the 
duration of the experiment. A flask of cells derived from same cell population 
was named “R1” and exposed to a starting dose (500nM) of the BRAF inhibitor. 
The drug concentration was increased up to 1.25µM dabrafenib.  After 4 months 
of continued exposure to the drug, the resistant polyclonal R6 cell line was 
obtained. From the R6 resistant cell line, single cell cloning was performed and 
derived into 5 dabrafenib resistant clones: 3C, 3F, 5E, 7E and 9D.  
 
Single cell cloning by limited dilution of suspension cells 
1x10^6 cells in 3mL of complete growth media in a 6 well plate, were seeded. 
Then 100µL aliquot of the cells was diluted 1:20 in 2mL of conditioned media 
(50% of 20% FCS RPMI 1640 and 50% sterile stroma cell medium). Then four 
vials containing 5mL of conditioned media were prepared, and from the 1:20 
 Functional characterization of BRAF mutations in multiple myeloma  
57 
 
stock different dilutions were transferred: 1:500, 1:250, 1:166 and 1:125. After 
mixing, 96 well plates (4 plates in total) were prepared for each dilution 
containing 50µL/per well. Cells were incubated at 37°C 5%CO2 and 
cryopreserved until use.  
 
Senescence-associated β-galactosidase (SA-β-gal) assay 
1x10^6 cells in 3mL of complete growth media in a 6 well plate, were seeded. 
For positive control, cells were treated with 75µM H2O2 for 2h followed by a 
wash and further incubation for 4 days then coverslips were fixed with 1 × 
fixative solution using the Senescence β-galactosidase staining kit. Staining of 
cells fixed on coverslips was performed according to manufacturer’s 
instructions. Lastly, 200 μL β-galactosidase staining solution was added to each 
coverslip then samples were incubated at 37 °C without CO2 for 16 h. The 
coverslips were washed twice with 1 × PBS, fixed in 100% ethanol and air-dried. 
Coverslips were mounted with Vectashield. Images were taken using a Zeiss 
Axiovert microscope92. 
 
Development of tetraploid U266 cells 
U266 cells were seeded with a density of 1.5x10^6 cells/mL in RPMI1640 with 
10%FCS, until reach approximately 30x10^6 cells in total. Then cells were 
treated with 5µM cytochalasin B (Sigma, Aldrich, Munich, Germany) for 16h and 
released for 48h to interrupt cytokinesis and induce tetraploidy. After that, live-
cell staining was performed with 1:1000 Hoechst 33342 (10mg/mL) for 40 
minutes at 37°C and 5%CO2.  
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Phosphoproteomics 
Preparation of SILAC media 
Cell culture media SILAC RPMI 1640 was prepared for stable isotope labeling 
with amino acids (SILAC) as indicated in the table.  The fetal calf serum dialyzed 
(dFCS) was heat inactivated at 56°C for 30 minutes, and centrifuged at 4500rpm 
for 10 minutes. It was stored at -20°C until use.  
 
Double SILAC 
The protein expression profiling of the U266-R cells was performed as follows, 
the starting culture was with 3x106 cells in flasks 25cm2 with 10mL SILAC 
media; for the parental cell line (untreated) was labeled with light amino acids 
while, the resistant clones (treated) were labelled with heavy amino acids. 2 to 
5mg of proteins was required which is obtained harvesting 5x107-108 cells in 
total.  
 
Triple SILAC 
For the protein expression profiling of the OPM-2 BRAF WT/V600E, 3x106 cells 
in flasks 25cm2 with 10mL SILAC media, the OPM-2 cells were labeled with light 
amino acids, OPM-2 BRAF WT were labeled with medium amino acids and OPM-
2 BRAF V600E with heavy amino acids. Cells were expanded until harvesting 
5x107-108 cells in total. 
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SILAC protein lysates  
Harvested cells were washed with 1X PBS and resuspended in an appropriate 
volume of NP40-Lysis buffer (20µL lysis buffer per 106 cells). Then the samples 
were incubated on ice for 20 minutes.  Samples were centrifuged at 15000rpm 
for 10 minutes at 4°C. The supernatant was transferred to a new tube and 
subjected to sonication (Branson Ultrasonics, Danbury, Connecticut, USA) at 
15W output with 3 burst of 10 seconds each. Then lysates were stored at -80°C.   
Electrospray Ionisation Mass Spectrometry of the samples was kindly managed 
by Dr. Diego Yepes and Dr. Thomas Oellerich from the Hematology Oncology 
Department of the Frankfurt am Main University Clinic, DKTK/DKFZ Germany. 
Data was analyzed through the use of QIAGEN’s Ingenuity® Pathway Analysis 
(IPA®, QIAGEN Redwood City,USA). 
 
High-throughput data analysis 
High-throughput data from gene expression microarray and proteomics were 
analyzed in different bioinformatics software packages as the database for 
annotation, visualization and integrated discovery (DAVID),  PANTHER database 
and QIAGEN’s Ingenuity® Pathway Analysis (Huang, Lempicki, and Sherman 
2009; Thomas et al. 2003, IPA® QIAGEN Redwood City,USA).  
 
Flow cytometry  
Suspension cells were washed with 1XPBS and resuspended in 250µL of 1XPBS. 
Then 700µL of ice-cold methanol were added dropwise, while slowly vortexing 
the tube. The fixed cells were incubated at 4°C for at least 1 hour.  
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Equally number of cells per sample (1x106 cells) were washed with 10mL 
1XPBS. A propidium iodide (PI) working solution was prepared 1:100 PI 
(1mg/mL) in 1XPBS, and with 1:40 RNase A 10mg/mL). 200µL of the working PI 
solution was added to the samples, followed by incubation at room temperature 
for 30 minutes.  
The collection of data was done in an Accuri C6 flow cytometer (BD Biosciences, 
Heidelberg, Germany) and the analysis of cell cycle was through the BD Accuri 
C6 software (BD Biosciences, Heidelberg, Germany). 
 
FACS sorting of cells  
Samples before sorting were resuspended with high density in PBS 1X and 15ml 
receiving tubes were prepared with 3mL media. Sorting of cells was done with 
100µM nozzle and drop delay was calculated per experiment in a FACS BD Aria I 
or FACS BD Fusion I sorters (Becton Dickinson, Franklin Lakes, NJ, USA) and 
performed by Klaus Hexel or Tobias Rubner from the Core Facility Flow 
Cytometry at DKFZ, Heidelberg, Germany.   
 
Indirect immunofluorescence  
Cells grown on coverslips were briefly rinsed with PBS and then fixed in ice-cold 
methanol/acetone for 7 minutes. Coverslips were blocked in 10% goat serum in 
PBS for 30 minutes and incubated with primary antibodies for 1 hour.  
A complete list of the primary antibodies used for immunofluorescence is 
provided in Table.  
Table 19. Primary antibodies used for immunofluorescence 
Antigen Clone Species Clonality Dilution Source 
EGR-1 44D5 rabbit monoclonal 1:400 Cell Signaling 
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Technology 
BRAF C-19 rabbit polyclonal 1:200 Santa Cruz 
BRAF V600E VE-1 mouse monoclonal undiluted 
Dr. med. David Capper, 
Pathology Institute, 
Neuropathology, 
Heidelberg University 
Followed of primary antibody incubation, the coverslips were washed three 
times for five minutes in 1X PBS and incubated with appropriate species-specific 
secondary antibodies. Proceeded with three 1XPBS washes, and washed once 
with ddH2O. Coverslips were mounted in Vectashield antifade mounting 
medium (Vector Laboratories, Burlingame, CA, USA) with DAPI for Fluorescence 
or DNA was counterstained with Hoechst 33342 (10 mg/mL), diluted 1:1000 in 
1XPBS. Coverslips were analyzed by fluorescence microscopy on a Zeiss Cell 
Observer.Z1 system equipped with an AxioCam MRm camera (Carl Zeiss, 
Göttingen, Germany), or an Axiovert 200M equipped with an AxioCam MRm 
camera (Carl Zeiss, Göttingen, Germany). Then for image analysis the software 
ZEN lite 2011 (Carl Zeiss, Göttingen, Germany) was employed. 
 
A complete list of the secondary antibodies used for immunofluorescence is 
provided in Table 20. 
Table 20. Secondary antibodies used for immunofluorescence 
Antigen Fluorochrome Species Clonality Dilution Source 
Mouse IgG Alexa Fluor 488 
Goat 
polyclonal 
 
1:1000 
 
Molecular Probes Life 
Technologies 
 Rabbit IgG Alexa Fluor 488 
Mouse IgG Cy3 Dianova (Jackson 
immuno Research) 
 Rabbit IgG Cy3 
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Gene transfer techniques 
Transduction 
Lentiviral production – transfection of 293t cells  
The day before transfection, 1x10^6 Lenti-X™ 293T cells were seeded in a 10cm 
dish in 10mL fresh medium to obtain 50-80% confluency on the day of lentiviral 
production. 
Immediately before transfection in 6 cm plate, a mixture of 3 plasmids was 
prepared with 1.8µg of packaging plasmid (psPAX2), 300ng envelop plasmid 
(pMD2.G) and 3µg expression plasmid along with 20µL RPMI 1640.  The cell 
transfection was performed with TransIT®-LT1 Transfection Reagent (Mirus 
Bio LLC, Madison Wisconsin, USA) according to manufacturer’s instructions. 
TransIT®-LT1 is a cationic polymer that forms stable positively charged 
complexes with DNA, allowing its delivery to cells. The transfection reagent was 
diluted with RPMI 1640 and incubated 5 minutes at room temperature. Then the 
plasmid mixture was diluted with the transfection reagent and incubated 20 
minutes at room temperature. The mix was added to 6mL of fresh DMEM 
medium. The medium in the cells was removed and replaced with the mix, 
followed by incubation at 37°C overnight.  
Next day, the medium was replaced with 2,7mL DMEM + 30% FCS with 
Pen/Strep. On the third day, harvesting of the virus was collected and stored at 
4°C; cells received fresh media. On the fourth day, a second harvesting was 
performed and filtered with 0.22μm filters (Millipore, Bedford, USA). The 
presence of virus (>5 x 105 IFU/ml) was confirmed by Lenti-X™ GoStix™ 
according to manufacturer’s instructions (Clontech Laboratories, Inc. A Takara 
Bio, Shiga Japan). 1mL viral soup aliquots were stored at -80°C.  
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Lentiviral infection of human cell lines 
The cells to be infected were plated in a 6 well culture plate, and 0.8µL of 
Polybrene (10mg/mL, Santa Cruz Biotechnology Heidelberg, Germany), were 
added per 1mL medium. Then 300µL of viral soup was transferred to 1.5x10^5 
cells in 1mL and incubated at 37°C overnight.  The following day, the medium 
was replaced with fresh medium and after 48h cells were under antibiotic 
selection.  
 
Transfection 
Transfection of adherent cell lines was performed with a cationic polymer, 
Lipofectamine® 3000 Reagent (Thermo Fisher Scientific, Lafayette; USA), 
according to manufacturer’s instructions. The day before transfection, 1x10^5 
cells were seeded on coverslips in 6 well plates (Greiner-Bio-One GmbH, 
Frickenhausen Germany) with 3mL fresh RPMI or DMEM.  
 
Statistical analysis 
Statistical analysis was performed using Excel software (Microsoft Corporation, 
Redmond, USA) and GraphPad Prism 7 software (GraphPad Software La Jolla, 
CA, USA). Experiments consisted in technical and biological replicates and were 
in triplicates unless otherwise is specified.  Microarray statistical significance 
was analyzed by two group empirical Bayes test.  For biological and functional 
gene analysis the right-tailed Fisher’s exact test was performed. Significances 
were calculated by two-tailed t test or two-way ANOVA methods. False discovery 
rate (FDR) <0.05. The value of P<0.05 was considered significant. 
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Results 
 
 
Conditional BRAF V600E OPM-2 model 
In order to investigate biological sequelae of BRAF V600E expression in multiple 
myeloma, we established an inducible model system. MM cell lines that are 
available in the laboratory were sent for targeted sequencing of genes that 
included: KRAS, NRAS, and BRAF. The MM cell line OPM-2 was chosen among 
other myeloma cell lines such as RPMI-8226, U266, L363, MM1.S, SKMM.1, and 
INA-6 because of its wild type KRAS, wild type NRAS, and wild type BRAF status. 
In the Tet-On system, gene expression is conditionally obtained upon addition of 
tetracycline (Tet) or doxycycline (Dox) to the cell culture medium. The 
RAS/RAF-WT OPM-2 cells were co-transduced with both vectors containing the 
regulatory plasmid and response plasmid, and conditional target gene 
expression (c: conditional, cBRAF-WT or cBRAF V600E, respectively) was 
examined in presence of Dox by immunofluorescence or immunoblotting (Figure 
5). Conditional overexpression of the mutant cBRAF V600E was detected using a 
mutation-specific antibody. Likewise, the inducible cBRAF WT expression was 
confirmed by immunoblotting, serving as control of the mutant protein. Once 
that the presence of the inducible protein was confirmed, the conditional cells 
 Functional characterization of BRAF mutations in multiple myeloma  
65 
 
were under clonal selection by limiting dilution to generate conditional stable 
clones 
 
Characterization of mutant BRAF in MM cells 
In order to reveal the consequences of conditional BRAF expression, we 
examined cell growth, gene expression, protein expression and phosphorylation 
profile of both cells overexpressing BRAF wild type or mutant.  
Although MAPK/ERK pathway mutations in MM have been identified, the 
mechanism of action by which activated BRAF contributes to this disease needs 
to be further elucidated. Therefore, we investigated gene expression of the 
human myeloma OPM-2 cell line with conditional expression of BRAF V600E by 
cDNA microarray analysis and compared their gene expression patterns to OPM-
2 cBRAF wild type. In total, 1788 genes were differentially expressed in OPM-2 
cBRAF V600E compared to OPM-2 cBRAF WT cells (log2FC <-1 and >1, p-value 
<0.05 and FDR 0.05). Of these, 1014 genes were down- and 774 were 
upregulated in cBRAF V600E compared to cBRAF WT MM cells (Figure 7 ). 
 Ingenuity Pathway Analysis (IPA) software was used to sort differentially 
expressed transcripts to functional categories (data not shown). The most 
significantly canonical pathways included diverse hints towards DNA damage 
response (Figure 7). It has been reported that mutant BRAF can lead to 
oncogenic stress which induces DNA damage and subsequently can result in 
oncogene-induced senescence (Vredeveld et al. 2012). Moreover, using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) we 
classified the functionally related genes by their enrichment score (ES)93. 
Prominent gene groups revealed were, for example, negative cell growth (ES: 
2.16), programmed cell death (ES: 1.63) and microtubules (ES: 1.36), etc. (Figure 
7).  
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To test the effect on proliferation of the conditional model, OPM-2 cells were 
maintained in 10% FCS RPMI 1640 and induced with Dox, but no differences 
were observed upon overexpression of either cBRAF wt or cBRAF V600E (Figure 
5E). AS OPM-2 cells might depend on other pathways to proliferate and survive 
irrespective of their BRAF status, we subjected the cells to starvation media  1% 
FCS RPMI 1640 followed by Dox treatment. However, no growth differences 
were observed(data not shown). The mutated kinase does not offer any growth 
advantages and there was no slowdown in the growth in the mutant clones. In 
addition, to find out if senescence was a result of conditional BRAF 
overexpression, a senescence-associated β-galactosidase (SA-β-gal) assay was 
performed. However, no changes were observed in induced cBRAF V600E in 
comparison to cBRAF  wild type or uninduced despite the suggestive gene 
expression profiling (Figure 6B).  
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Figure 5. Inducible expression system of BRAF wild type or mutant in multiple 
myeloma. A. BRAF Tet-On system. B Immunofluorescence of induced cBRAF wild type and 
mutant IRES mcherry and DAPI for nucleus. C. Immunoblot of dependence of protein 
expression level on concentration of doxycycline. D. After single cell cloning of the 
transduced parental cell lines, the clones obtained were induced with doxycycline and the 
expression of the conditional proteins was confirmed by immunoblotting. Unmodified OPM-
2 cell line was included as control. D. Growth of inducible BRAF OPM-2 cell lines. Trypan blue 
exclusion growth measurements were generated from OPM-2 cBRAF cells.  There were no 
significant  growth differences among the groups. 
 Functional characterization of BRAF mutations in multiple myeloma  
68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Senescence in conditional BRAF wild type or mutant in multiple myeloma. A. 
β-Galactosidase staining on normal OPM-2 at population doubling 30 (left) and stress-
induced premature senescence induced using 75µM peroxide hydrogen (H2O2) for 2h, 
followed by a wash and further incubation for 4 days. B. Cells were induced with 1µg/mL 
doxycycline for 24h followed by wash and further incubation for 48h. No oncogene induced 
senescence was observed in the cBRAF model. 
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Protein expression profiling and phosphoproteomics of 
cBRAF OPM-2 
In order to understand the biological consequences of BRAF V600E in MM, 
differential protein and phosphoproteome expression of the wild type versus 
mutant kinase was performed by using stable isotope labeling by aminoacids in 
cell culture (SILAC) in combination with protein enrichment and LC-MS/MS 
analysis. The distribution histograms of the protein expression profiling and 
Figure 7. Gene expression profiling of induced cell lines expressing cBRAF WT or 
V600E. A.  The inducible OPM-2 cell lines cBRAF wild type or V600E were under doxycycline 
(1µg/mL) for 24h, subsequently RNA was extracted and the gene expression profile was 
assessed using the Illumina HT12v4 platform followed by hierarchical clustering in  Chipster 
(M Aleksi., et al. 2011). B. Analysis of canonical pathways in Ingenuity Pathway Analysis (IPA, 
Qiagen). D. DAVID Top ten functional clusters (Huang DW et al. 2009). Log2FC <-1 to >1 and 
FDR p-value <0.05. 
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phosphoproteome of SILAC cBRAF OPM-2 fit a Gaussian distribution, which 
satisfies the criteria for protein quantification (Supp. Figure 21). Follow up on 
the analysis demonstrated upregulation of EGFR signaling including proteins 
related to MAPK/ERK pathway and molecules associated with DNA replication 
were downregulated (Figure 8). The differential expression of BRAF V600E 
versus BRAF wild type showed active proteins involved in the MAPK/ERK 
pathway such as BRAF, MEK1/2 ERK2 and ELK-1, which is consistent with our 
previous results (Figure 9). 
An integrative assessment of our analyses of the transcriptome, proteome, and 
phosphoproteome indicates that conditional expression of mutant BRAF 
promotes DNA damage response through diverse signaling including nucleotide 
excision repair (NER), DNA double–strand break repair by NHJE, BRCA1 in 
damage response, etc. (Figure 7B, 10A and 10B). Nevertheless, OPM-2 cBRAF 
V600E cell proliferation showed no difference in comparison to BRAF wild type 
(Figure 5E). This is potentially explained by the mutational background of OPM-
2 which affects main effectors of growth arrest such as p53 and CDKN2A. 
 
 Figure 8. Distribution of protein expression profiling and phosphorylation in OPM-2 
cBRAF V600E. SILAC labeling of OPM-2 cells expressing cBRAF V600E (H) compared against 
cells expressing cBRAF wild type (M). The expression was normalized against non-modified 
OPM-2 cells (L).  Log2 plot for quantified proteins and phosphopeptides.  
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Figure 9. Quantitation of MAPK/ERK proteins in OPM-2 cBRAF V600E by SILAC. The 
histograms represent the quantitative data obtained for cBRAF V600E (H) normalized to 
OPM-2 cells (L) and compared to cells expressing cBRAF wild type (M) normalized to OPM-2 
cells (L).  Log2 fold change plot for quantified protein and phosphopeptides. p>0.01, **- 
0.01≥p>0.001, *** - p≤ 0.001,****  p≤ 0.0001 
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Figure 10. Canonical pathways in OPM-2 cBRAF V600E. A. Ingenuity’s canonical 
pathways of protein expression profiling and stack bars showing the percentage of down- 
(green) and upregulated (red) protein expression. B. IPA analysis of canonical pathways of 
phosphoproteome and stack bar showing lower phosphorylation (green) or high 
phosphorylation (red).  
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BRAF inhibition and MEK inhibition in cBRAF OPM-2. 
To explore cell response under BRAF inhibitors, mutant cells were treated either 
with vemurafenib, a BRAF V600E specific inhibitor or dabrafenib, a mutant 
BRAF V600 inhibitor but with wider target range including wild type B-RAF and 
C-RAF. In both cases, we observed the paradoxical activation of the native BRAF 
protein in the immunoblot by downstream ERK phosphorylation, although this 
activation occurs more moderately in cells under dabrafenib. This effect has also 
been observed in melanoma which is associated with the induction of neoplasia 
such as cutaneous squamous cell carcinoma (cuSCC) 55 (Figure 11 ).  This is 
caused by BRAF inhibitor-mediated homodimerization and heterodimerization 
of non-mutant RAF isoforms, leading to pathway activation rather than 
inhibition. Interestingly, the presence of BRAF V600E by the conditional 
expression is fully abrogating the paradoxical activation of the still present WT 
BRAF kinase (Figure 11A and 11B). Importantly, the employment of 
downstream inhibitors, such as the MEK inhibitor trametinib (Figure 11C), 
abrogates the activation of the pathway without the paradoxical activation, 
supporting the combination of both inhibitor families, as approved for 
melanoma and also now under clinical investigation in multiple myeloma. 
 
 
 
 
 
 
 
Figure 11. Targeted therapy of BRAF V600E. 
Cells overexpressing BRAF V600E were under 
different drug concentrations of two BRAF 
inhibitors, A. Vemurafenib and B. Dabrafenib 
and a C. MEK inhibitor, trametinib. The 
conditional cells were induced for 24h with 
doxycycline followed by treatment of 
vemurafenib and trametinib 1h and dabrafenib 
24h 
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Dabrafenib resistant multiple myeloma 
model  
To understand possible mechanisms underlying clinical drug resistance in MM, a 
Dabrafenib resistant model was established using the multiple myeloma U266 
cell line carrying the BRAF K601N mutation, which we confirmed by panel 
sequencing. U266 is the only known MM cell line carrying an activating BRAF 
mutation 95,96. A U266 resistant cell line (U266 R6) was created by long-term 
exposure to increasing concentrations of the kinase inhibitor. In addition, 
parental U266 cells (not exposed to dabrafenib) were kept in culture in parallel 
to U266 R6 over the same period of time to serve as controls (Figure 12A). Then 
U266 R6 cell growth was analyzed and similar growth patterns were observed in 
comparison to parental cells (Figure 12B). 
From the resistant polyclonal cells U266 R6, single cell clones (U266R) were 
obtained by limiting dilution. To confirm specific resistance to the BRAF 
inhibitor, the cells were exposed to other chemotherapeutic agents to test for 
unspecific resistance through efflux pumps, increased drug metabolism, altered 
drug targets, etc.. Paclitaxel, Etoposide, 5-Fluoroacil, Vincristine, Doxorubicin 
and Cisplatin (Figure 13) were used as such control agents and we obtained five 
clones (1C-5C) with confirmed specific resistance to dabrafenib (Figure 12C). 
Specific resistance was also maintained after freeze and thaw cycles of the cell 
lines.  
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Figure 12. U266 resistant clones to dabrafenib. A. Scheme of development of the model. 
B. Growth curves of U266R and table showing the population doubling time. C.  Dose 
response curves where U266R cells were exposed to the indicated concentrations of 
dabrafenib for 72h and cell viability was measured by CellTiterGlo and expressed relative to 
control untreated cells (left panel). IC50 of dabrafenib in U266R cells (right panel). 
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Figure 13. U266R resistant clones and chemotherapeutic agents. Proliferation of U266 
resistant clone cells following 72h with the indicated chemotherapeutic agents. Cell viability 
was measured by CellTiter Glo and expressed relative to control untreated cells.  
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Whole Exome Sequencing in dabrafenib U266R resistant 
clones  
Once specific resistance to BRAF inhibitors was confirmed, next-generation 
sequencing was performed to identify mechanisms of drug resistance in the 
U266R model. A total of 96 SNVs and 45 indels were detected in exonic regions 
that were present in one or more resistant clones (Figure 14A and 14B). We 
focused on heterozygous mutations that were identically present in all resistant 
clones, and 3 candidates for dabrafenib resistance were identified. These were 
the serine/threonine kinase 36 (STK36), the calcium channel, voltage-
dependent, alpha 2/delta subunit 3 (CACNA2D3) and the Early Growth 
Response 1 (EGR-1) (Supp. Table 21). Subsequently, these aberrations were 
confirmed by Sanger sequencing. The drug resistance candidate gene chosen for 
further study was EGR-1 because it is downstream of the MAPK/ERK pathway 
(Figure 16A). Interestingly, the tumor variant frequency was approximately 20-
25% in all cases, which suggests that U266 resistant cell clones became 
tetraploid. Results from FiSH analyses in this regard confirmed tetraploidy 
(>80%) of resistant clones.  
From the whole exome sequencing of U266R differences in structural DNA 
rearrangement, copy number variations (CNVs) were detected in comparison to 
the reference genome of untreated parental cells (Figure 15). CNVs could 
contribute to the U266R phenotypic variation as an adaptative trait to 
dabrafenib treatment. Pathogenic CNVs are frequently related to an imbalance in 
gene dosage, such as gene amplification which is associated with drug 
resistance. Whether the selective pressure in our model with the BRAFi and the 
environmental conditions directly played a role in the generation of “somatic” 
CNVs in U266R or if it was due to a stochastic process is yet to be determined. 
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Figure 14. Whole exome sequencing U266 dabrafenib resistant cells. Frequency of A. 
single nucleotide variants and  B. indels in U266R. C. Pattern of nucleotide substitutions in all 
samples.  
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Figure 15. U266-R DNA copy number variants. Whole-exome view of U266 dabrafenib 
resistant clones. Coverage data are indicated as Normalized Log2 Ratios. Alternated 
green and black colors represent specific chromosomes from 1 (left) to X (right).   
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Hyperdiploidy in U266R 
After whole exome sequencing of U266R, a low, yet consistent tumor variant 
frequency was detected (20-25%) in all resistant clones, suggesting that cells 
acquired a tetraploid karyotype. To characterize the resistant clones, DNA ploidy 
analysis was performed by interphase FISH and metaphase FISH (Figure 16) and 
these experiments confirmed that U266 dabrafenib resistant clones developed a 
near-tetraploid karyotype in comparison to the near-diploid karyotype of 
parental untreated cells.  
To explore whether dabrafenib resistance was due to polyploidy, U266 cells 
were treated with a cytokinesis inhibitor, cytochalasin B. Then the DNA content 
was analyzed by flow cytometry and samples were sorted for tetraploidy 
content (purity >80%). Sorted cells were treated with dabrafenib for 72h. No 
significant differences were observed for these generated tetraploid cells in 
comparison to control cells (Figure 16C). Overexpression of EGR-1 was observed 
in purified tetraploid (purity after sorting 86.2%)  cells but not in cells before 
sorting (purity 1.7%) or overexpression of control proteins as alpha tubulin or 
RAS was not observed (data not shown).Thus, tetraploidy per se did not 
contribute to resistance it was observed in U266R.  
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Figure 16. Tetraploidy in U266R. A. Fluorescence in situ hybridization of U266R cell lines. 
Top: Representative FISH results shows duplicated gene copy number in a U266R clone in 
comparison to parental cells. Bottom: quantification of ploidy in U266R clones. Cytogenetic 
probes used PS 13-g 21-r, 18-b (1) and AML MDS 5q31-R 5q33-G 6cen-B (2). B. M-FISH 
images of U266. Parental cells (left) with near diploid karyotype (n=44) and U266R clone 1 
(right), showing near tetraploid karyotype with numerical and structural chromosomal 
instability. C. drug response curves of tetraploid sorted cells. No significative differences 
were observed.  
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Aberrant expression of EGR-1 confers dabrafenib 
resistance in U266R  
In this study, whole exome sequencing of U266R cells identified the frameshift 
insertion 994dupC (p. P332fs) in EGR-1, a candidate for dabrafenib resistance.  
The Early Growth Response 1 (EGR-1) is a nuclear protein and a member of the 
EGR family of C2H2-type zinc-finger proteins which binds to DNA motifs with 
the sequence 5'-GCG(T/G)GGGCG-3'.  The gene is encoded on plus strand of 
chromosome 5 from 137,801,169 to 137,805,103 and contains 1 intron and 3 
exons. As protein it is described as a transcriptional regulator with 543 
aminoacids (Figure 17B). EGR-1 expression is induced by growth factors, 
mitogens, ischemia, and tissue injury.  Then it binds to DNA and activate the 
transcription of several genes that are required for mitogenesis and 
differentiation 97–99.  
The frameshift insertion 994dupC  (p. P332fs) found by whole exome sequencing 
was confirmed by Sanger sequencing (Figure 18A). This aberration results in a 
premature stop codon which leads to the expression of a truncated transcript of 
292 amino acids losing the C-terminus of the protein. Our results demonstrated 
aberrant expression of EGR-1 in U266R with overexpression of wild type protein 
but also expression of a truncated protein which is observed at 50kDa in the 
immunoblot, while the wild type protein has a molecular weight of ~85KDa 
depending on posttranslational modifications (Figure 18B and 18C).   
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Figure 17. EGR-1 in MAPK pathway. A. scheme of MAPK pathway. Active mutant BRAF 
K601N promotes activation of downstream players of MAPK pathway including the 
transcription factor  EGR-1. B. Scheme of EGR-1 protein, it contains a repressor domain. It 
has a nuclear localization domain followed by three zinc finger that bind to DNA. EGR-1 has 
diverse posttranslational modifications sites such as phosphorylation, sumoylation and 
acetylation sites. C. The overall effect of this transcription factor is mainly determined by 
posttranslational modifications. Acetylation of EGR-1 by p300/CBP leads to cell growth, 
while phosphorylation by CSKII promotes apoptosis. Red arrow indicates indel 994dupC 
p.P332fs in U266R cells133.Copyright 2017 by Molecular Cell.  Modified and reprinted with 
permission 
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To explore EGR-1 expression under dabrafenib, cells were treated for 24h with 
increasing concentrations of the inhibitor followed by nuclear and cytoplasmic 
fractionation. Overexpression of wild type protein is observed in the nucleus in 
the resistant clone, along with expression of a truncated protein in nucleus and 
cytoplasm and both cell lines respond to the highest concentrations in 
comparison to parental cells (Figure 19A). To identify what occurred first during 
the development of this model, EGR-1 mutation or hyperdiploidy, samples from 
previous time points (2-3 months (R1 and R3, respectively) vs. 6 months (R6) 
under dabrafenib treatment) were studied by interphase FISH (5q31_5q33_6cen 
R1 with 90.85% positive tetraploid cells and 9-18% CIN and R3 with 77.98%  
positive tetraploid cells and 21-25% CIN) and by immunoblot (EGR-1 
overexpression, and expression of EGR-1 truncated), and both abnormalities 
were detected in the earliest steps of U266R development (data not shown).   
Further characterization of the aberrant EGR-1 expression in U266R was 
performed by treatment with actinomycin D, a transcription inhibitor and 
cycloheximide, a translation inhibitor, to distinguish the effect of these drugs on 
transcript levels and protein stability between wild type EGR-1 and truncated 
EGR-1. Downregulation of both wild type and the mutant EGR-1 was observed, 
therefore its overexpression is transcriptionally regulated (Figure 19 B and 
19C). Moreover, near-tetraploid U266 cells, generated by inhibiton of 
cytokinesis, showed an increased expression of this protein but not in the 
controls, suggesting that overexpression of EGR-1 in U266R could be caused by a 
gene-dosage effect  (Figure 16D).  
In order to elucidate if the aberrant expression of EGR-1 could confer resistance 
to dabrafenib, U266 cells were transduced with a lentiviral IRES GFPnuc vector to 
overexpress either wild type EGR-1 or truncated EGR-1. To analyze gene of 
interest expression, immunofluorescence microscopy and immunoblots were 
performed (Figure 20A and 20B). We observed differences in protein 
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localization, overexpressing EGR-1 wild type protein was co-localized in the 
nucleus, and however, truncated EGR-1 protein was mainly localized in the 
cytoplasm. This is likely to occur due to the loss of the zinc fingers so in 
consequence the protein cannot bind to DNA and its function as a transcription 
factor is abrogated.  Of note, growth curves of transduced cells were similar to 
non-transduced U266 cells (Figure 20C). Another consideration is the loss of 
posttranslational modifications such as phosphorylation at the C-terminus and 
acetylation which play a main role in the direction of the effect of this protein.  
It has been described in previous studies that EGR-1 can bind to p300/CBP, 
which acetylates the protein and promotes the transcription of growth-related 
factors such as FGF2, PDGFA, TGF- β and IGF-2. In contrast, when the protein is 
only phosphorylated it can promote the expression of factors associated with 
apoptosis like p53, PTEN, NF-κβ and BCL-2 100.  
To test if ectopic EGR-1 expression in U266 parental cells contributes to 
dabrafenib resistance, drug response curves of transiently transduced U266 
cells (FACS-sorted to > 95% purity) showed increased BRAFi resistance in cells 
overexpressing wild type EGR-1. Strikingly, nearly complete resistance was 
observed in cells expressing truncated EGR-1 (Figure 20D).  
To know if this is an exclusive mechanism of resistance for cells with BRAF 
K601N, preliminary experiments in A375 melanoma cell line carrying BRAF 
V600E transfected with EGR-1 wild type or mutant showed no difference in 
viability when cells were under dabrafenib (data not shown), therefore the 
interplay between mutation BRAF K601N and aberrant EGR-1  has to be 
elucidated. 
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Figure 18. Identification and analysis of indel EGR-1 found in U266 resistant clones. A. 
Sanger sequencing of U266R confirmed indel c.994dupC in gene EGR-1. As is observed in the 
chromatograms, the frameshift is present in the resistant clones but not in the parental U266 
non-treated cells. B. RT-PCR and C. western blot of EGR-1 expression in U266R.  
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Figure 19. Characterization of EGR-1 expression in U266R cells. A. Immunoblot of 
nuclear and cytoplasmic fractions of U266 parental cells and a resistant clone treated with 
increasing concentrations of dabrafenib for 24h. Overexpression of EGR-1 wild type in 
U266R is mainly found in the nucleus while mutant protein is also found in cytoplasm. 
Higher ERK1/2 phosphorylation is observed in resistant clone. B.  Immunoblot (up) and RT-
PCR (down) of time course of U266R cells treated with 5µg/ml actinomycin. Decreased 
expression of EGR-1 is observed at 30min in all samples.  C. Western blot of EGR-1 
expression in U266R under a time course with 100µg/ml cycloheximide.  Downregulation of 
EGR-1 expression is observed at 2h across samples.  
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Figure 20. EGR-1 overexpressed in  U266 cells. A. Immunofluorescence of lentiviral 
transduced U266 cells with EGR-1 IRES GFPnuc vector. B Western blot of U266 
overexpressing EGR-1 wild type or mutant. C. Growth curve of U266 EGR-1 showed no 
difference in comparison to controls. D. Drug response curves of U266 EGR-1 under 
Dabrafenib for 72h and IC50 showed significant differences in cells overexpressing EGR-1 
wild type and EGR-1 mutant  in contrast to controls. 
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Conclusions and Discussion  
 
BRAF mutations in multiple myeloma 
BRAF mutations are found in a variety of solid and hematological tumors. These 
aberrations occur more frequently in the activation domain of this kinase 
conferring hyperactivation of the MAPK/ERK pathway which triggers cell 
proliferation, differentiation and survival.  
Recurrent aberrations in BRAF have been described mainly in hairy cell 
leukemia, melanoma, and thyroid cancer, among other malignancies, which has 
allowed for the development of successful targeted therapies. However, rapid 
drug resistance can develop, and a high number of resistance mechanisms have 
been discovered. Therefore, it is important to overcome this resistance with new 
therapeutic strategies. 
Recently, activating BRAF mutations have been reported in multiple myeloma 
patients while the functional characterization of these mutations in this disease 
remains elusive. 
The work presented here demonstrates the potential biological impact of BRAF 
V600E mutation and a novel BRAF inhibitor resistance mechanism in multiple 
myeloma.   
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BRAF V600E in OPM-2 multiple myeloma cells 
In this study, an in vitro model conditionally expressing BRAF wild type or BRAF 
V600E was developed and used to subsequently investigate the influence of this 
aberration on the biology of myeloma cells.  
Previous studies have shown that constitutive activation of the MAPK/ERK 
pathway in immortalized human fibroblasts harboring the BRAF V600E 
mutation can induce either cell cycle progression or cell cycle arrest in the G1 or 
G2-M phases depending on expression of tumor suppressors such as p19ARF or 
p16INK4a which hinder the activity of cyclin-dependent kinases (CDKs), thereby 
preventing DNA replication. For example, silencing a tumor suppressor by using 
p16INK4a shRNA, in the same cells abolished cell cycle arrest and increased cell 
proliferation 101,102.  
In melanoma, the mutated kinase is associated with proliferative advantages and 
cellular differentiation.  What is more, in 50% of melanoma cases, present loss of 
function of p16INK4a and ARF genes.103 In vitro melanoma studies abrogating 
the function of the tumor suppressors p53, RB and ARF, resulted in unlimited 
cell proliferation and oncogenic transformation102.  
However, in a conditional BRAF V600E model in rat thyroid PCCL3 cells, 
expression of the mutant kinase leads to increased DNA synthesis, chromosomal 
instability, dedifferentiation, and apoptosis 104.  
Oncogenic stress can be caused hyperactivation of the MAPK/ERK pathway due 
to an activating BRAF mutation which could lead to hyper-replication, causing 
replication factor exhaustions; fork stalling/collapse and triggering DNA 
damage, promoting growth arrest.  
The MAPK/ERK pathway also plays a role in DNA damage response (DDR) by 
facilitating DNA repair through the regulation of ataxia-telangiectasia mutated 
(ATM) and Rad3-related kinase (ATR)105. Furthermore, it has been 
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demonstrated that low levels of DNA strand breakings (DSBs) increased ERK 
and AKT phosphorylation through the ATM-AKT-ERK path as a pro-survival 
signaling. However, the pro survival signaling is overridden in case of excessive 
DNA damage due to the triggering of ATM-independent phosphatases that 
inhibit ERK signaling 106,107.  
In multiple myeloma, our conditional model of overexpression of BRAF V600E 
resulted in a highly active MAPK/ERK pathway, however, changes in either 
proliferation or senescence were not observed in comparison to controls. The 
most likely explanation for this lack of phenotype is that we introduced the 
BRAF mutation as secondary event in late stage MM cells, i.e. a MM cell line, 
already depend on other oncogenic mechanisms and have already acquired 
mechanisms to overcome checkpoints against malignant transformation.   
The OPM-2 cell line used here, for example, has a p53 mutant (R175H) protein 
which abolishes the wild type tumor suppression function of this protein 108.  In 
addition, OPM-2 has a CDKN2A mutation (H83Y) which leads to reduced ability 
to promote cell cycle arrest 109. Both of these proteins are main regulators of the 
cell cycle progression, hence if there is an oncogenic insult without sustained 
p53/Rb activation cBRAF (c: conditional BRAF expression) V600E OPM-2 cells 
may not be able to undergo growth arrest and are likely to escape from 
senescence. 
This would be in line with our results showing diverse simultaneous activations 
of DNA repair pathways by overexpression of BRAF V600E. Of note, no 
mutations of participating molecules in DNA repair pathways are present in 
OPM-2 cells. In consequence, it is possible that cBRAF V600E induced DNA 
damage can be solved by the DNA repair machinery in OPM-2 cells.  
The mutational background of the OPM-2 cells may also compensate pro-
apoptotic signals related to stress by DNA damage through different means. For 
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example, PTEN loss present in OPM-2 contributes to apoptosis resistance since it 
is a direct regulator of the PI3K/Akt pathway, which mediates survival in cancer 
cells 110. Furthermore, OPM-2 harbors mutant FGFR3 K650, which confers 
activation of this receptor being associated with activation of the MAPK/ERK 
pathway likely contributing to OPM-2 cell proliferation 111,112.  
 
Dabrafenib resistance in multiple myeloma 
Currently, targeted therapy with BRAF inhibitors such as vemurafenib and 
dabrafenib are first line treatments for several mutant BRAF cancers. 
Nevertheless, drug resistance in BRAF inhibitors-treated patients frequently 
developed within the first year of treatment. Understanding the mechanisms of 
resistance is critical for the development of better therapeutic strategies. 
Frequently single BRAF inhibitor treatment resistant mechanisms include 
continuous MAPK/ERK pathway activation65,72,81,83,113.   
The activating BRAF K601N/E is a mutation found in melanoma, colorectal 
cancer, bladder cancer, prostate cancer, lung adenocarcinoma among others 
types of cancer 96,114.  In contrast to BRAF V600E there is only very limited data 
on resistance mechanisms of BRAF K601N/E positive cells after initial response 
to dabrafenib. 
We developed an in vitro model of resistance using the U266 MM cell line, which 
harbors BRAF K601N, by long-term culture under increasing concentrations of 
dabrafenib, followed by limiting dilution single cell seeding to generate the 
U266R stable resistant clones. In this work, U266R was established as an in vitro 
dabrafenib resistant model was established and was characterized by whole 
exome sequencing, cytogenetics, and proteomics. 
Within the abnormalities detected in U266R by whole exome sequencing diverse 
mutations including single nucleotide variants, frameshift insertions, frameshift 
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deletions and structural and numerical aberrations like copy number variations 
and tetraploidy were found in this model. 
 
Tetraploidy in U266R 
In all clones of U266R a high degree of tetraploidy was observed by interphase 
FISH and metaphase FISH. Tetraploidy occurs when there is a mitotic arrest, e.g. 
in absence of microtubules, resulting in failed cell division.  Why the U266R cells 
developed a near-tetraploid karyotype is unclear.  
Next generation sequencing confirmed a common polymorphism in TP53, P72R, 
in U266 cells, which is reported to affect the G1 arrest gene function which may 
explain why U266R polyploid cells progressed through the cell cycle and 
proliferated 115,116.   
On the other side, hyperdiploidy is frequently reported in multiple myeloma, and  
is a relevant prognostic factor for the risk stratification of this disease and 
accounts for up to 50% of MM patients 117. Moreover, the U266 cell line 
intrinsically carries a small near-tetraploid population of cells (4-8%), which by 
clonal evolution may have been enriched by the BRAFi treatment.  Polyploidy 
could provide diverse cancer advantages like chromosomal instability (CIN) that 
leads to further evolution of the malignancy, and it has been described that 
tetraploid cells can overcome oncogene-induced senescence by overexpressing 
DNA repair genes to reduce DNA damage response and have epigenetic 
modifications to silence p53118–120.  . To know if this karyotype contributed to 
the resistant phenotype of U266R cells, naïve U266 cells were induced for 
tetraploidy with a cytokinesis inhibitor, and treated with dabrafenib. Similar cell 
viability was observed in tetraploid generated U266 and control cells. Therefore 
tetraploidy alone did not trigger BRAFi resistance in our model of BRAF mutant 
multiple myeloma.  
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EGR-1 drives resistance to BRAF inhibition in multiple 
myeloma 
Whole exome sequening to our dabrafenib resistance model U266R led to the 
identification of aberrant EGR-1 expression in U266R since it overexpresses 
EGR-1 wild type and truncated EGR-1 (frameshift insertion 994dupC). We could 
show that this aberrant expression is transcriptionally regulated and 
overexpression of both protein variants confers dabrafenib resistance to a 
different degree in multiple myeloma. Noteworthy, EGR-1 is a transcription 
factor regulated by MAPK/ERK signaling that promotes the expression of factors 
such as EGF-R ligands resulting in a positive feedback loop within the same 
signaling pathway.  
Interestingly, upregulation of JUN has been shown to be associated with BRAFi 
resistance121,122. One of the target genes of JUN is EGR-1, that in turn upregulates JunB. 
Some of the targets of JunB include EGF ligands, TNF, CACNA2D3 and STK36. The last 
two genes were also found to be mutated in WES and validated by Sanger sequencing in 
U266R (data not shown).   
Moreover, EGR-1 overexpression has been reported in prostate cancer where 
this transcription factor triggers the expression of different targets like IGF-II, 
PDGF-A and TGF-β leading autocrine cell growth 123. In melanoma, it has been 
reported that mutant BRAF activated ERK1/2 leading to EGR-1 overexpression 
which stimulates the synthesis of fibronectin promoting tumor cell invasion 124. 
Recent studies in multiple myeloma identified new frequent gene mutations in 
EGR-1 including missense mutations125.  While EGR-1 knockdown in this disease 
has been associated with bortezomib resistance, this study showed for the first 
time that EGR-1 overexpression confers dabrafenib resistance in BRAF-driven 
multiple myeloma. 
Diverse posttranslational modifications occur in EGR-1 such as acetylation at the 
KDKK site by p300/CBP which stabilizes EGR-1 and promotes cell survival. This 
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protein has few characterized phosphorylation sites. These include S378, T391, 
and T526, which are phosphorylated by casein kinase II as a stress response 
favoring cell death. It has been described that p19ARF sumoylates EGR-1 at site 
K272 and promotes its nuclear translocation. In addition, EGR-1 is ubiquitinated 
and degraded in the proteasome (Figure 17C) 97, 98,100,101.  
The truncated EGR-1 protein in our model loses the zinc fingers and diverse 
sites for posttranslational modifications that may affect the interaction of this 
transcription factor to DNA and probably to other protein partners. 
A high number of transcription factors are proteins with intrinsically disordered 
(ID) regions/domains (i.e. not well defined secondary/tertiary structures) which 
are important for their biological function. The ID sequences are flexible and 
allow protein-protein and protein-DNA interactions, often accompanied by 
conformational changes of both, proteins and DNA. The ID regions can be a 
platform for macromolecular interactions, allowing the cooperation between 
transcription factors and other coregulatory proteins modifying the chromatin 
to allow an efficient and selective gene regulation. The case of unbound (free) 
forms of transcriptions factors with ID regions is poorly studied, but it is likely 
that the scaffold property is still present 126.   
Protein sequence analysis of both EGR-1 wild-type and truncated showed a 
shared identity of 89.04% (Figure 21A). Analysis of intrinsically unstructured 
proteins predicts that EGR-1 is a disordered protein along its entire length with 
a disorder tendency of 0.602 in average (max. 1), this means that in its native 
unbound state it does not have a well-defined tertiary structure. An advantage of 
this scenario is that EGR-1 can interact specifically its corresponding interaction 
partners (Supplementary Fig. 22) and rapidly without excessive binding 
strength 127,128. Moreover, unstructured proteins can be flexible linkers 
suggesting that EGR-1, when unbound to DNA, may work as a scaffold protein. 
Interestingly, truncated EGR-1 shows higher disorder tendency of 0.685 than the 
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whole protein length (Figure 21 B). The lack of the zinc fingers of the truncated 
EGR-1 impede DNA binding, thereby abrogating the conformational changes 
associated to this interaction and likely leaving the scaffold capacity intact, 
which may favor the association with other proteins triggering certain cell 
responses, such as dabrafenib resistance.  In contrast EGR-1 wild type retains its 
DNA-binding capability. However, the excess of EGR-1 wild type protein 
detected in our U266R model, may also work as a scaffold protein. And therefore 
possibly explain why also EGR-1 wild type, when overexpressed, confers some 
resistance to dabrafenib, while the truncated version of EGR-1, losing its DNA-
binding capacity, confers even a higher degree of resistance.  
Some of the predicted protein partners which may interact with motifs of EGR-1 
include GRB2, STAT3, STAT5, TRAF2, TRAF6, CK1, GSK3, NEK2, PKA and 
SUMO129.  Although further studies are necessary to fully understand the precise 
role of EGR-1 (wild type and truncated) in the context of dabrafenib resistance, 
this is a first approach to explain the complexity of this transcription factor and 
functional protein association networks.   
Furthermore, this is the first study to show that EGR-1 aberrant expression is a 
BRAFi resistance mechanism in multiple myeloma. Understanding diverse BRAFi 
resistance mechanisms will lead to new therapeutic approaches. 
Strategies to overcome BRAFi resistance include the use pan-RAF-inhibitors 
which block all RAF isoforms, a combination of BRAF inhibitors with 
downstream MAPK inhibitors or combinatorial therapy targeting several cell 
pathways like PI3K/Akt pathway. Another approach to improve patient 
outcomes is intermittent BRAFi administration50,54,67,84,130. 
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Figure 21. Bioinformatic analysis of EGR-1 wild type and EGR-1 mutant.  
A. Multiple-Sequence Alignment of EGR-1 wild type and EGR-1 mutant (indel 994dupC) 
protein sequences by CLUSTAL MUSCLE (3.8) Asterisks show identical amino acids. Colons 
and semi-colons display conserved substitutions and semi-conserved substitutions, 
respectively 134. B. IUPRED predictions (Long disorder) of intrinsic disorder (ID) for EGR-1 
wild type and EGR-1 mutant (indel 994dupC). Values above 0.5 are considered 
disordered127,128 .  
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Outlook 
 
BRAF V600E  
The present work demonstrates that conditional BRAF V600E expression in 
OPM-2 cells leads to differentially expressed genes and proteins mainly 
associated with DNA repair mechanisms. Although, the MAPK/ERK pathway was 
highly activated by this mutation neither a proliferative nor a senescent 
phenotype was observed in this model. DNA damage has been associated with 
this aberration in other cancers. However, further validation should be 
conducted for this disease. On the other side, this model has contributed to 
further knowledge about this heterogeneous disease and gives a tool to 
investigate rational therapy approaches. Following this, two BRAF inhibitors 
showed the paradoxical effect on BRAF wild type in MM cells and how MEK 
inhibition can abolish the activation of the pathway, which is consistent with 
previous studies in other types of cancer. Further studies are necessary to fully 
describe the effect of this mutation in multiple myeloma. Physiologic BRAF 
V600E models are necessary since there is a lack of MM cell lines carrying this 
mutation. Different approaches could be followed for this end either by genetic 
manipulation of MM cell lines or by successful establishment of primary cell 
lines carrying the BRAF V600E mutation.  
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EGR-1 aberrant expression 
Overexpression of EGR-1 has been associated with tumor progression and tumor 
cell invasion in diverse types of cancer. Moreover, EGR-1 mutant (p.332fs) and 
wild type overexpression lead to dabrafenib resistance in multiple myeloma 
which is a new BRAFi resistance mechanism. Although an extensive 
characterization was performed for our U266R model, additional follow-up 
studies are important to support our findings. Furthermore, the detailed 
mechanistic role of EGR-1 in a BRAF K601N mutation context needs to be 
clarified.  
A challenge is the lack of BRAF mutant multiple myeloma cell lines. However, 
there is another BRAF K601N cell line in public depositories, JVM-3, which can 
be transduced with EGR-1 (wild type and mutant) and tested for dabrafenib 
resistance. Another point to consider is that BRAF K601N only moderately 
activates the MAPK/ERK pathway in comparison to BRAF V600E For this reason 
our group is collaborating to do an in silico modeling of the mutant protein to 
predict how interacts with BRAFi. 
Moreover, we examined if the resistance was also found in BRAF V600E and 
truncated EGR-1 carrying cells, but preliminary data in A375 melanoma cell line 
showed that is not the case, nevertheless to be certain, additional experiments 
should be conducted in diverse cell lines under similar conditions. An alternative 
would be to introduce both mutations to recreate the same conditions and test 
for drug resistance.  
Regarding the study of EGR-1 properties as a disordered and scaffold protein, 
the first step would be to do bioinformatics analysis to identify EGR-1 critical 
amino acids residues for the interaction with other proteins and modeling in 
silico of native and truncated EGR-1 to predict the dynamics and biochemical 
nature of this transcription factor. Another way to characterize ID proteins 
states is the use of nuclear magnetic resonance. Followed by the analysis of 
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intracellular protein-protein interactions (co-immunoprecipitation, pull-down 
assay) and the identification of possible EGR-1 binding proteins by MALDI-
QIT/TOF MS. To validate these results, the generation of mutant EGR-1 (native 
and truncated) lacking the ability to interact with a possible interaction partners 
could be performed.  
This is one of the first studies of BRAF inhibitor resistance mechanisms in 
multiple myeloma. Discovering a new resistance mechanism such as EGR-1 
wildtype overexpression and, even more potent, truncated EGR-1 in a BRAF 
K601N context allows us to understand more about the biological complexity of 
this disease and opens an opportunity to design new and better therapeutic 
approaches. 
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Figure 21 Protein expression profiling and phosphoproteome of SILAC cBRAF OPM-2 
A.  Abundance of phosphorylated aminoacids Serine (S), Threonin (T) and Tyrosine (Y) from 
phosphoproteome of cBRAF OPM-2cells. B. Distribution of normalized protein expression of 
cBRAF V600E cells (H) vs. cBRAF wt (M), it follows a normal distribution. C. Distribution of 
protein expression left, cBRAF wt (M) vs. OPM-2 (L) skewed to the right and right cBRAF mut 
(H) vs. OPM-2 (L).  
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Table 21.Whole exome sequencing single nucleotides variants (SNVs).  
Gene Chromosome 
Position 
(bp) 
RefSeq 
Nucleotide 
change 
(bp) 
Aminoacid 
change 
Tumor 
Variant 
Frequency 
(TVF) 
AAMDC 11 77583291 NM_024684 c.C299A  .A100E 0.1 
AKAP3 12 4736483 NM_001278309 c.G1585C p.V529L 0.16 
AMZ1 7 2742434 NM_001284355 c.G383A p.R128H 0.33 
ANKMY2 7 16664685 NM_020319 c.T293G p.V98G 0.07 
ANTXR2 4 80906014 NM_001145794 c.A1045G p.I349V 0.38 
ANXA1 9 75777742 NM_000700 c.G520A p.G174R 0.25 
AP1M1 19 16344329 NM_001130524 c.C1109T p.A370V 0.22 
APBB1 11 6417099 NM_145689 c.G1876A p.G626S 0.14 
ARMC6 19 19153596 NM_001199196 c.T106G p.F36V 0.05 
ARSI 5 149676805 NM_001012301 c.A1682G p.N561S 0.23 
ASH1L 1 155451994 NM_018489 c.C667G p.L223V 0.13 
ATG2A 11 64681941 NM_015104 c.C203T p.S68L 0.14 
BCL11A 2 60687763 NM_022893 c.A2284T p.R762X 0.08 
C11orf49 11 47008832 NM_001003678 c.A120C p.Q40H 0.2 
CCDC141 2 179702171 NM_173648 c.G3775C p.G1259R 0.19 
CDKL5 X 18622565 NM_003159 c.A1521T p.Q507H 0.43 
CELSR2 1 109807612 NM_001408 c.G5587T p.G1863W 0.34 
CFAP53 18 47788439 NM_145020 c.A220G p.I74V 0.28 
CNOT3 19 54647480 NM_014516 c.G253C p.E85Q 0.1 
CNTN2 1 205034929 NM_005076 c.G1708T p.G570W 0.24 
CR1 1 207760836 NM_000651 c.G5636A p.G1879E 0.06 
CTRL 16 67963859 NM_001907 c.A773T p.N258I 0.26 
CYP2C8 10 96827432 NM_000770 c.G185T p.G62V 0.2 
DNHD1 11 6555133 NM_144666 c.G2728T p.D910Y 0.07 
DNMT1 19 10246816 NM_001379 c.C4589A p.P1530H 0.2 
DOCK1 10 129202616 NM_001380 c.A3982C p.I1328L 0.13 
DOCK10 2 225688253 NM_014689 c.A3148G p.R1050G 0.26 
EIF1B 3 40353004 NM_005875 c.G239A p.G80E 0.12 
EPB41L5 2 120918480 NM_020909 c.T1817A p.V606E 0.15 
ETV4 17 41622711 NM_001079675 c.C85A p.R29S 0.2 
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FAAH 1 46871718 NM_001441 c.G794T p.G265V 0.11 
FAM114A1 4 38910315 NM_138389 c.A760G p.T254A 0.15 
FAM20A 17 66596777 NM_017565 c.A31G p.T11A 0.26 
FMO2 1 171168615 
   
0.1 
FOSB 19 45973903 NM_001114171 c.G143A p.G48E 0.22 
GDA 9 74838058 NM_001242507 c.T407C p.V136A 0.27 
GRIA2 4 158255211 NM_000826 c.T1205C p.L402P 0.08 
HEATR1 1 236738199 NM_018072 c.T3089C p.V1030A 0.08 
HINFP 11 119001438 NM_015517 c.A185G p.E62G 0.21 
HLA-B 6 31324641 NM_005514 c.A167T p.Q56L 0.15 
HTR1A 5 63257087 NM_000524 c.G460A p.A154T 0.33 
IGHMBP2 11 68704032 NM_002180 c.A2084G p.K695R 0.2 
IMPDH2 3 49065219 NM_000884 c.G455A p.S152N 0.27 
IQSEC2 X 53280267 NM_015075 c.G876T p.E292D 0.5 
ISM1 20 13260432 NM_080826 c.A530T p.D177V 0.19 
ITPR2 12 26811022 NM_002223 c.C1928A p.T643N 0.32 
KCNAB1 3 156232232 NM_172159 c.G684T p.E228D 0.04 
KCNMA1 10 78704560 NM_001161352 c.G2873A p.S958N 0.2 
KLHL7 7 23183521 NM_001031710 c.C670G p.P224A 0.09 
KRT34 17 39535422 NM_021013 c.T1009C p.S337P 0.09 
KRTAP4-6 17 39296172 NM_030976 c.G568T p.V190F 0.44 
LMBR1 7 156516850 NM_022458 c.T1181G p.I394S 0.18 
MAP7 6 136693664 NM_001198619 c.G413A p.R138H 0.24 
MCC 5 112720680 NM_001085377 c.A400G p.S134G 0.19 
MST1 3 49725034 NM_020998 c.A310T p.T104S 0.13 
MSX2 5 174151777 NM_002449 c.C115T p.R39C 0.11 
MTMR10 15 31240510 NM_017762 c.A1372G p.K458E 0.22 
MUC2 11 1097266 NM_002457 c.G6670T p.D2224Y 0.06 
MYH10 17 8473117 NM_005964 c.G647A p.R216Q 0.73 
MYO3B 2 171239640 NM_138995 c.G1126C p.V376L 0.17 
MYRF 11 61549237 NM_001127392 c.G2957A p.R986Q 0.13 
NFE2L3 7 26224568 NM_004289 c.C1250T p.S417F 0.12 
NKD1 16 50666257 NM_033119 c.A761G p.E254G 0.2 
OR1D5 17 2966085 NM_014566 c.G817T p.A273S 0.48 
OR2T34 1 248737347 NM_001001821 c.G712A p.G238S 0.09 
OR4Q3 14 20216464 NM_172194 c.C878G p.T293S 0.1 
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PABPC3 13 25671027 NM_030979 c.A691G p.K231E 0.06 
PANX2 22 50617645 NM_052839 c.A1973G p.Q658R 0.16 
PCDH18 4 138452383 NM_019035 c.G860T p.S287I 0.07 
PLA2R1 2 160832646 NM_001007267 c.T2528G p.L843R 0.21 
PSD4 2 113956667 NM_012455 c.A2777G p.Q926R 0.11 
PTPRF 1 44086525 NM_130440 c.C5354A p.T1785K 0.24 
PTTG1IP 21 46276150 NM_004339 c.C407T p.A136V 0.21 
RNF170 8 42711445 NM_001160223 c.T634A p.Y212N 0.15 
RNF217 6 125397953 NM_001286398 c.T1432C p.Y478H 0.06 
ROR1 1 64515503 NM_001083592 c.C304A p.P102T 0.1 
RTEL1 20 62326254 NM_016434 c.C3270G p.D1090E 0.14 
SATL1 X 84363163 NM_001012980 c.T812A p.M271K 0.37 
SBNO1 12 123801894 NM_001167856 c.A2809G p.I937V 0.2 
SFR1 10 105883785 NM_145247 c.A410G p.Q137R 0.14 
SLC10A4 4 48485624 NM_152679 c.C46T p.R16W 0.35 
SNX31 8 101612653 NM_152628 c.A698G p.E233G 0.2 
SPATA31D1 9 84608678 NM_001001670 c.A3293C p.D1098A 0.16 
SSPO 7 149519194 NM_198455 c.C12998G p.S4333C 0.2 
STK31 7 23802525 NM_001260504 c.C1330T p.R444C 0.17 
STK36 2 219540912 NM_001243313 c.C595T p.P199S 0.1 
STRN4 19 47236473 NM_001039877 c.A560G p.Y187C 0.35 
TMC3 15 81625596 NM_001080532 c.C2467A p.H823N 0.27 
TMEM245 9 111782778 NM_032012 c.C2602T p.R868C 0.17 
TOPAZ1 3 44283561 NM_001145030 c.C16A p.P6T 0.2 
TSPAN17 5 176083136 
   
0.28 
TTLL2 6 167754021 NM_031949 c.C633A p.C211X 0.24 
UHRF2 9 6460598 NM_152896 c.A670T p.M224L 0.24 
UNC80 2 210769606 NM_182587 c.C4486A p.L1496I 0.26 
ZNF831 20 57767600 NM_178457 c.T1526G p.F509C 0.14 
ZYX 7 143080059 NM_003461 c.C667T p.H223Y 0.05 
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